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A B S T R A C T
Background
Cardiovascular disease (CVD) is a major cause of disability and mortality globally. Premature fatal and non-fatal CVD is considered
to be largely preventable through the control of risk factors via lifestyle modifications and preventive medication. Lipid-lowering and
antihypertensive drug therapies for primary prevention are cost-effective in reducing CVD morbidity and mortality among high-risk
people and are recommended by international guidelines. However, adherence to medication prescribed for the prevention of CVD
can be poor. Approximately 9% of CVD cases in the EU are attributed to poor adherence to vascular medications. Low-cost, scalable
interventions to improve adherence to medications for the primary prevention of CVD have potential to reduce morbidity, mortality
and healthcare costs associated with CVD.
Objectives
To establish the effectiveness of interventions delivered by mobile phone to improve adherence to medication prescribed for the primary
prevention of CVD in adults.
Search methods
We searched CENTRAL, MEDLINE, Embase, and two other databases on 21 June 2017 and two clinical trial registries on 14 July
2017. We searched reference lists of relevant papers. We applied no language or date restrictions.
Selection criteria
We included randomised controlled trials investigating interventions delivered wholly or partly by mobile phones to improve adherence
to cardiovascular medications prescribed for the primary prevention of CVD. We only included trials with a minimum of one-year
follow-up in order that the outcomemeasures related to longer-term, sustained medication adherence behaviours and outcomes. Eligible
comparators were usual care or control groups receiving no mobile phone-delivered component of the intervention.
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Data collection and analysis
We used standard methodological procedures recommended by Cochrane. We contacted study authors for disaggregated data when
trials included a subset of eligible participants.
Main results
We included four trials with 2429 randomised participants. Participants were recruited from community-based primary care or
outpatient clinics in high-income (Canada, Spain) and upper- to middle-income countries (South Africa, China). The interventions
received variedwidely; one trial evaluated an intervention focused on blood pressuremedication adherence delivered solely through short
messaging service (SMS), and one intervention involved blood pressure monitoring combined with feedback delivered via smartphone.
Two trials involved interventions which targeted a combination of lifestyle modifications, alongside CVD medication adherence, one
of which was delivered through text messages, written information pamphlets and self-completion cards for participants, and the
other through a multi-component intervention comprising of text messages, a computerised CVD risk evaluation and face-to-face
counselling. Due to heterogeneity in the nature and delivery of the interventions, we did not conduct a meta-analysis, and therefore
reported results narratively.
We judged the body of evidence for the effect of mobile phone-based interventions on objective outcomes (blood pressure and
cholesterol) of low quality due to all included trials being at high risk of bias, and inconsistency in outcome effects. Of two trials targeting
medication adherence alongside other lifestyle modifications, one reported a small beneficial intervention effect in reducing low-density
lipoprotein cholesterol (mean difference (MD) -9.2 mg/dL, 95% confidence interval (CI) -17.70 to -0.70; 304 participants), and the
other found no benefit (MD 0.77 mg/dL, 95% CI -4.64 to 6.18; 589 participants). One trial (1372 participants) of a text messaging-
based intervention targeting adherence showed a small reduction in systolic blood pressure (SBP) for the intervention arm which
delivered information-only text messages (MD -2.2 mmHg, 95% CI -4.4 to -0.04), but uncertain evidence of benefit for the second
intervention arm that provided additional interactivity (MD -1.6 mmHg, 95% CI -3.7 to 0.5). One study examined the effect of blood
pressure monitoring combined with smartphone messaging, and reported moderate intervention benefits on SBP and diastolic blood
pressure (DBP) (SBP: MD -7.10 mmHg, 95% CI -11.61 to -2.59; DBP: -3.90 mmHg, 95% CI -6.45 to -1.35; 105 participants).
There was mixed evidence from trials targeting medication adherence alongside lifestyle advice using multi-component interventions.
One trial found large benefits for SBP and DBP (SBP: MD -12.45 mmHg, 95% CI -15.02 to -9.88; DBP: MD -12.23 mmHg, 95%
CI -14.03 to -10.43; 589 participants), whereas the other trial demonstrated no beneficial effects on SBP or DBP (SBP: MD 0.83
mmHg, 95% CI -2.67 to 4.33; DBP: MD 1.64 mmHg, 95% CI -0.55 to 3.83; 304 participants).
Two trials reported on adverse events and provided low-quality evidence that the interventions did not cause harm. One study provided
low-quality evidence that there was no intervention effect on reported satisfaction with treatment.
Two trials were conducted in high-income countries, and two in upper- to middle-income countries. The interventions evaluated
employed between three and 16 behaviour change techniques according to coding using Michie’s taxonomic method. Two trials
evaluated interventions that involved potential users in their development.
Authors’ conclusions
There is low-quality evidence relating to the effects of mobile phone-delivered interventions to increase adherence to medication
prescribed for the primary prevention of CVD; some trials reported small benefits while others found no effect. There is low-quality
evidence that these interventions do not result in harm.On the basis of this review, there is currently uncertainty around the effectiveness
of these interventions. We identified six ongoing trials being conducted in a range of contexts including low-income settings with
potential to generate more precise estimates of the effect of primary prevention medication adherence interventions delivered by mobile
phone.
P L A I N L A N G U A G E S U M M A R Y
Interventions delivered by mobile phone to help people adhere to medication to prevent cardiovascular disease
Review question
We reviewed the evidence on the effect of interventions delivered by mobile phone to help people in taking their medication to prevent
cardiovascular disease (for example, heart attacks and strokes). We found four studies which included 2429 participants.
Background
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Around 17.6 million people die from cardiovascular disease every year.Medications can help to prevent cardiovascular disease; however,
many people who have been given these medications do not take them as often or as consistently as recommended. This means that
the medication will not work as well as it could to prevent cardiovascular disease. Interventions delivered through mobile phones, for
example, prompting by text messaging, may be a low cost way to help people to take their medication as recommended.
Study characteristics
The evidence is up to date to June 2017. We found four studies that tested interventions delivered at least partly by mobile phone,
which followed up participants for at least 12 months.
Key results
We were not able to combine the results of the four trials because the interventions were very different. The studies were at high risk of
bias and the effects of the interventions were inconsistent across studies, and so, we are not confident about their findings. The evidence
suggests that interventions delivered by mobile phone may help people to take their medication, but the benefits are small, and some
trials found that the interventions did not have any beneficial effect. There was no evidence to suggest that these types of interventions
caused harm. The results of trials currently being conducted should tell us the effects of these types of interventions more accurately,
and will tell us if they work in a wider range of contexts, including low-income countries.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mobile phone interventions compared to usual care for improving adherence to medication prescribed for primary prevention of cardiovascular disease
Patient or population: people prescribed medicat ion for primary prevent ion of cardiovascular disease
Setting: community-based primary care or outpat ient clinics in high-income (Canada, Spain) and upper- to middle-income countries (South Af rica, China)
Intervention: mobile phone-based intervent ions
Comparison: usual care
Outcomes Impact of participants
(studies)
Quality of the evidence
(GRADE)
Cholesterol (low-density lipoprotein)
f ollow-up: range 1-2 years
1 study found evidence of a small bene-
f icial intervent ion ef fect on reducing LDL-
C (-9.20 mg/ dL), and 1 study found a very
small increase in LDL-C (0.77 mg/ dL) with
wide conf idence intervals that included no
ef fect
893
(2 RCTs)
⊕⊕©©
Lowa,b
Systolic blood pressure
f ollow-up: range 1-2 years
3 of the 4 studies found lower systolic
blood pressure with mobile phone inter-
vent ions, but the size of ef fect varied. 2
studies showed moderate and large re-
duct ions in systolic blood pressure (-7.10
and -12.45 mmHg). 1 mult i-arm trial found
small reduct ions with information-only text
messages (-2.1) and interact ive text mes-
saging (-1.6 mmHg) arms. 1 study found
a slight increase in blood pressure (0.83
mmHg) but with wide conf idence intervals
that included no ef fect
2194
(4 RCTs)
⊕⊕©©
Lowa,b
Diastolic blood pressure
f ollow-up: range 1-2 years
2 of 3 studies found lower diastolic blood
pressure with mobile phone intervent ions,
but the size of the ef fect varied. 2 stud-
ies showed large and small reduct ions in
diastolic blood pressure (-12.23 and -3.
90 mmHg), and 1 study found a slight in-
998
(3 RCTs)
⊕⊕©©
Lowa,b
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crease in diastolic blood pressure (1.64
mmHg) but with wide conf idence intervals
that included no ef fect
Combined CVD events Not reported (0 studies) -
Adverse events
f ollow-up: range 1-2 years
1 study reported that there were 0 adverse
events attributable to the intervent ion. 1
study report that there was no dif ference
between groups in experience adverse ef -
fects of stat ins, and that 0 part icipants re-
ported intervent ion-related adverse events
1500
(2 RCTs)
⊕⊕©©
Lowb,c
Cognitive outcome: satisfaction with
treatment
f ollow-up: mean 1 year
1 study measured sat isfact ion with treat-
ment, and found no evidence of a dif -
ference between intervent ion and control
arms
1190
(1 RCT)
⊕⊕©©
Lowd,e
LDL-C: low-density lipoprotein cholesterol; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for inconsistency: trial results included large variat ions in the degree to which the outcome was
af fected.
bDowngraded one level for risk of bias: all t rials at unclear risk of bias on mult iple domains.
cDowngraded one level for imprecision: very low number of events.
dDowngraded one level for indirectness: based on a single trial conducted in a single sett ing (public sector clinic in Cape
Town, South Af rica).
eDowngraded one level for risk of bias: trial at unclear risk of bias on two domains.
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is a major cause of disability and
mortality throughout the world (Naghavi 2017; WHO 2011;
WHO 2016), with an estimated 17.6 million people dying from
CVDs in 2016, accounting for 32% of all global deaths (Naghavi
2017). However, premature fatal and non-fatal CVD is considered
to be largely preventable through the control of risk factors (WHO
2011).
Primary prevention of CVD refers to actions taken to reduce the
incidence of clinical events due to coronary heart disease (CHD),
cerebrovascular disease and peripheral vascular disease, among
people with risk factors who have not yet developed clinicallyman-
ifest CVD (WHO 2007). Primary prevention of CVD consists of
lifestyle modifications (e.g. smoking cessation, increasing physical
activity) and drug therapy (Piepoli 2016).
Lipid-lowering and antihypertensive drug therapies for primary
prevention are cost-effective in reducingCVDmorbidity andmor-
tality among high-risk people and are recommended by interna-
tional guidelines (Piepoli 2016; WHO 2007). Recommendations
relating to the use of antiplatelet drugs for primary prevention
vary. The European Society of Cardiology (ESC) states that as-
pirin cannot be recommended in primary prevention due to its
increased risk of major bleeding (Piepoli 2016); however, the US
Preventive Services Task Force (USPSTF) recommends the use of
aspirin when the 10-year risk of CVD events reaches such a level
that the benefits of aspirin, in terms of CVD events prevented,
outweigh the potential harm of increased gastrointestinal haem-
orrhage (USPSTF 2014).
Adherence to long-termmedication is not ideal and results in costs
in both health and economic terms (Piepoli 2016). Meta-analyses
have estimated rates of adherence to cardiovascular medications
ranging from 50% to 60% (Chowdhury 2013; Naderi 2012),
and there is some evidence that adherence is lower for primary
prevention (Naderi 2012).
One study of health records of over 430,000 people in UK general
practices found that 47% of people prescribed statins for primary
preventiondiscontinued treatment (indicated by a greater than90-
day gap between prescriptions), among whom, 72% then restarted
treatment (Vinogradova 2016). One study of Finnish healthcare
registers found that 53% of women prescribed statin therapy for
primary prevention were adherent (defined as exceeding 80% of
the prescribed regimen) (Lavikainen 2016). It has been estimated
that approximately 9% of cases of CVDs in the EU could be at-
tributed to poor adherence to vascular medications (Chowdhury
2013). Improving adherence to medications for the primary pre-
vention of CVD would help to maximise the clinical benefits for
the wider population (WHO 2003). Therefore, there is consider-
able scope for increasing adherence to prescribed medicine, and
so, reducing morbidity, mortality and healthcare costs.
Description of the intervention
Mobile phone ownership is almost universal in high-income coun-
tries and estimated to have reached over 90% in low- and middle-
income countries (ICT 2016). Given the broad reach of mobile
phones and the potential for automation of delivery, interventions
delivered by mobile phone are a potentially cost-effective strategy
to improve medication adherence. A range of media can be deliv-
ered through mobile phones including text messages, picture mes-
sages, interactive-voice response, telephone calls and, with increas-
ing ownership of smart phones with Internet capabilities (ICT
2016), mobile applications.
How the intervention might work
A wide range of factors have been shown to be associated with
medication non-adherence (DiMatteo 2004; Julius 2009; Kardas
2013; Pound 2005; Vermeire 2001; WHO 2003). Mobile phone-
based interventions have the potential to target a number of these
factors. For example, lack of adherence resulting from lack of in-
formation regarding the benefits of medication, lack of informa-
tion about how they work and how to take them, misconceptions
about medication adverse effects, complex or unclear advice or
poor recall of information provided in consultations may be ad-
dressed through text messages providing short and simply worded
snippets of information (Julius 2009; Kardas 2013; Pound 2005;
Vermeire 2001). Experiences of adverse effects can be targeted
through mobile phone-delivered interventions by providing in-
formation about medication and facilitating a link to a healthcare
professional for people experiencing problems with their medica-
tion. Lack of social support has also been linked to poor medi-
cation adherence and previous qualitative research found that the
receipt of text message-based intervention provided social support
(Douglas 2013). Mobile phone-delivered interventions can be de-
signed to target psychological factors such as lack of motivation
and low self-efficacy (Free 2016).
Existing interventions targeting adherence to CVD medication
have employed mobile technologies to: deliver medication re-
minders (Park 2014a); encourage self-monitoring of medication
intake (Park 2014a); encourage habit formation relating to med-
ication-taking behaviours (Bobrow 2014); provide information
(Bobrow 2014; Park 2014a); and facilitate links to healthcare ser-
vices where required (Bobrow 2014; Piette 2012).
Systematic reviews assessing the effect of mobile health (mhealth)
interventions on medication adherence for a range of condi-
tions, including HIV, non-communicable diseases and prevention
of transplant rejection have reported significant improvements
(Anglada-Martinez 2015; Park 2014b), and an RCT found mo-
bile phone messaging to be effective in improving contraceptive
use (Smith 2015). Few adverse effects of mobile phone-based in-
terventions have been reported; potential, but rare, adverse events
may include road traffic accidents (Caird 2014).
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Why it is important to do this review
Systematic reviews evaluating the effect of mhealth interven-
tions have reported promising but inconclusive results relating
to improved medication adherence, including adherence to med-
ication for secondary prevention of heart disease (Adler 2017;
Anglada-Martinez 2015; Park 2014b). However, no systematic re-
view has specifically examined the effect of mobile phone-based
interventions on adherence tomedications for the primary preven-
tion of CVD. Mobile phone-based interventions are of particular
interest given their low-cost and potential for widespread delivery.
O B J E C T I V E S
To establish the effectiveness of interventions delivered by mobile
phone to improve adherence to medication prescribed for the pri-
mary prevention of CVD in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of parallel group
design that randomised by participant or by cluster. We did not
include cross-over trials as this design would be inappropriate for
assessing effects on cardiovascular events or mortality, due to the
irreversible nature of these events. We only included trials with a
minimum of one-year follow-up in order that the outcome mea-
sures relate to longer-term, sustained medication adherence be-
haviours and outcomes. We included studies published as full text
and as abstract only, and unpublished data.
Types of participants
We included adults (aged 18 years and over) who have been pre-
scribed medication for the primary prevention of CVD. As this re-
view focused on the primary prevention of CVD,we only included
studies involving participants who had not had a prior CVDevent,
defined as: a previous myocardial infarction, stroke, revascularisa-
tion procedure (coronary artery bypass grafting or percutaneous
coronary intervention), people with angina, and people with an-
giographically defined CHD. Where we identified trials that in-
cluded a subset of eligible participants, we contacted the authors
to request data for only those participants of interest. When we
were unable to access these data, we applied a cut-off whereby
only trials in which at least 75% of participants met the criteria
for primary prevention were included.
Types of interventions
We included trials of interventions delivered wholly or partly
by mobile phone to improve adherence to cardiovascular med-
ications prescribed for the primary prevention of CVD. We
included interventions targeting adherence to antihypertensive
drugs (thiazide-like diuretic, angiotensin-converting enzyme in-
hibitor, calcium channel blocker, beta-blocker); lipid-lowering
drugs (statins); and antiplatelet drugs (low-dose aspirin, non-as-
pirin antiplatelet drugs). We only included trials targeting adher-
ence to at least one of these medications. We also included trials of
interventions that targeted medication adherence alongside other
lifestyle modifications.
Intervention
Any mobile phone-specific delivery mechanism, including short
messaging service (SMS), multimedia messaging (MMS), appli-
cations (apps) and Interactive Voice Response. We included inter-
ventions employing amix of deliverymechanisms of which at least
one was mobile phone-based, for example, interventions delivered
by mobile phones in combination with traditional methods such
as face-to-face communication and links to other types of support
(e.g. healthcare support worker, telephone calls, Internet pages).
Comparator
Usual care and active controls where the control group interven-
tion had no component delivered by a mobile phone-specific de-
livery mechanism.
Types of outcome measures
Primary outcomes
• Objective measures of adherence to treatment (low-density
lipoprotein cholesterol (LDL-C), total cholesterol (TC) and
high-density lipoprotein cholesterol (HDL-C), for the effect of
statins; blood pressure for antihypertensive drugs; heart rate for
the effect of atenolol; urinary 11-dehydrothromboxane B2 for
the antiplatelet effects of aspirin).
• Combined CVD events (fatal or non-fatal events).
• Adverse effects including self-reported road traffic accidents.
Secondary outcomes
• Indirect measures of adherence to treatment (self-report,
tablet counts, medication event monitoring systems, pharmacy
prescription data).
• Fatal cardiovascular events.
• Non-fatal cardiovascular events (CHD, stroke).
• Health-related quality of life assessed using validated
instruments (e.g. 36-Item Short Form Health Survey (SF-36),
EQ-5D).
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• Cognitive outcomes (any measures of: satisfaction with
treatment, medication-taking self-efficacy, autonomy related to
medication, attitudes (e.g. concerns about medicine adverse
effects)).
• Costs.
We also reported on the following process measures: extent of in-
tervention received (e.g. number of text messages received, mea-
sures of use of allocated mobile application) and acceptability of
intervention.
Reporting one or more of the outcomes listed here in the trial was
not an inclusion criterion for the review.
Where outcomes (primary or secondary) were measured at multi-
ple time points, we extracted data for the final point of measure-
ment.
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2017, Issue 6);
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 21
June 2017);
• Embase (Ovid, 1980 to 2017 week 25);
• CINAHL Plus (EBSCOhost, 1937 to 21 June 2017);
• Conference Proceedings Citation Index-Science (CPCI-S)
on Web of Science (Thomson Reuters, 1990 to 21 June 2017).
The search strategies are presented in Appendix 1. The Cochrane
sensitivity-precision maximising RCT filter was applied to MED-
LINE (Ovid) and adaptations of it to the other databases, except
CENTRAL (Lefebvre 2011).
We
carried out a search of ClinicalTrials.gov (www.ClinicalTrials.gov)
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP) Search Portal (apps.who.int/
trialsearch/) for ongoing or unpublished trials on 14 July 2017.
We imposed no restriction on date or language of publication.
We did not perform a separate search for adverse effects of mobile
phone-based interventions targeting medication adherence. We
considered adverse effects described in included studies only.
Searching other resources
We checked the reference lists of all included studies and reviewed
relevant articles for additional references. We also examined rele-
vant retraction statements and errata for included studies.
Data collection and analysis
Selection of studies
Two review authors (MP and SB) independently screened the titles
and abstracts of all identified potential studies to decide whether to
retrieve the full text (eligible or potentially eligible/unclear studies)
or to discard the study. Two review authors (MP and SB) indepen-
dently screened the retrieved full texts to identify studies for inclu-
sion and identify and record reasons for exclusion of the ineligible
studies in theCharacteristics of excluded studies table.We resolved
any disagreements though discussion, and where necessary, a third
review author (CF) arbitrated. We excluded any duplicates. We
collated multiple reports of the same RCT into a single entry. We
completed a PRISMA flow diagram (Liberati 2009).
Data extraction and management
We used a standardised, prepiloted form to extract data from the
included studies for assessment of study quality and evidence syn-
thesis. We contacted chief investigators for additional information
where necessary. We extracted the following information.
• Methods: study design; total duration of study; study
setting and date of study.
• Participants: number randomised; number lost to follow-
up/withdrawn; number analysed; mean age; age range; gender;
proportion meeting criteria of ’primary prevention’; and
inclusion criteria and exclusion criteria.
• Interventions: intervention; comparison; concomitant
medications; excluded medications; intervention delivery
mechanism (text messages/MMS/mobile application/combined);
how intervention was developed; behaviour change technique(s)
employed; if intervention was personalised; and frequency and
duration of intervention receipt.
• Outcomes: primary and secondary outcomes specified and
collected; adverse effects; and time points reported.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (MPandSB) independently extracted data and
resolved any differences by returning to the original study reports
and discussion with a third review author (CF) where necessary.
One review author (MP) transferred data into the ReviewManager
5 (Review Manager 2014). To ensure that there were no errors in
data entry, one review author (SB) checked that the data entered
into Review Manager 5 were consistent with those in the data
extraction form.
Assessment of risk of bias in included studies
Two review authors (MP and SB) independently assessed the risk
of bias for each study using the criteria detailed in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
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For each of the following domains, we graded the potential bias
as high, low or unclear.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other biases.
We resolved disagreements by discussion. Where necessary, we
consulted a third review author (CF) to arbitrate. We constructed
a ’Risk of bias’ table including justifications for our judgements.
Where information relating to the risk of bias came from unpub-
lished data or correspondence with an author, we noted this. We
summarised the risk of bias judgements across different studies for
each of the domains listed. When considering treatment effects,
we accounted for the risk of bias for the studies that contributed
to that outcome.
Given the nature of the interventions included in this review, it
is likely that blinding of participants and personnel would be im-
possible, therefore, we expected trials to be categorised at high risk
of bias on this domain. For the overall study assessment, we cat-
egorised a trial as being at low risk of bias if it was rated as low
risk in all the domains listed above (with the exception of blinding
of participants and personnel). Trials that were at high or unclear
risk of bias on any of the domains (except blinding of participants
and personnel) were categorised as being at high risk of bias.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
report any deviations from it in the Differences between protocol
and review section (Palmer 2017).
Measures of treatment effect
We planned to analyse dichotomous outcome data as risk ratios
(RR) with 95% confidence intervals (CI). We planned to analyse
continuous outcome data as mean differences (MD) with 95%
CIs, or if a continuous outcome had been measured in multiple
ways, as a standardised mean difference (SMD) with 95% CIs. If
it had been applicable, we would have entered data presented as a
scale with a consistent direction of effect. If it had been applicable,
we would have reported any skewed data identified as medians
and interquartile ranges.
Unit of analysis issues
We did not carry out a meta-analysis because of the heterogeneity
of the included studies’ intervention content and delivery mecha-
nisms; as a result, we had no unit of analysis issues. Had we con-
ducted meta-analyses, we would have included RCTs with a par-
allel design, and if we had identified any cluster randomised trials,
we would have analysed the data accounting for clustering using
the intracluster coefficient. If we had identified multi-arm trials
for inclusion in meta-analyses, where there was more than one rel-
evant intervention arm but only one control arm, we would have
pooled the intervention arms for a single pair-wise comparison as
recommended by the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We planned to exclude intervention
arms not appropriate for this review.
Dealing with missing data
We contacted investigators to obtain further information where
necessary (e.g. when the study included a mixed population of
participants who met the criteria for primary prevention and par-
ticipants who met the criteria for secondary prevention, and when
only a subset of participants had been prescribed CVD preventive
medication). We also planned to contact investigators or study
sponsors to obtain missing data (e.g. when a study was identified
as abstract only). We planned that where this was not possible,
and the missing data were considered a potential source of serious
bias, we would conduct a sensitivity analysis to explore the impact
of including such studies in the overall assessment of results.
Assessment of heterogeneity
We considered the included trials to be too methodologically het-
erogeneous to pool the data in a meta-analysis. Therefore, we de-
scribed the studies narratively. We planned to use the I2 statistic
to measure heterogeneity across the trials for the analysis of each
outcome. In constructing the narrative forest plots for those out-
comes reported by multiple studies, we calculated the I2 statistic
and reported this. Had we considered the trials methodologically
similar enough to pool, and had we identified there to be moder-
ate to substantial heterogeneity (an I2 statistic between 30% and
100%), we would have reported it and examined possible causes
according to our prespecified subgroup analyses, subject to having
a sufficient number of studies.
Assessment of reporting biases
We did not use a funnel plot to explore possible small-study biases
for the primary outcomes as we only included four studies which
were too heterogeneous to pool in a meta-analysis. We planned
that if the results from more the 10 trials could be pooled, we
would use a funnel plot to explore possible small-study biases for
the primary outcomes.
Data synthesis
We planned to carry out meta-analyses only if it was meaning-
ful to do so (i.e. if the interventions, participants and outcome
measures were similar enough for pooling to make sense). We did
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not undertake meta-analyses as the included studies were too het-
erogeneous in the content and delivery of their interventions. We
presented the effect estimates for outcomes reported by multiple
studies on forest plots (without pooling); it should be noted that
in transferring effect estimates from papers into Review Manager
5 using the generic inverse variance method, some CIs differed
from those reported in the original paper by a decimal place.
Should more studies become available in future updates of this re-
view which enable meaningful meta-analyses, we plan to use fixed-
effect models. In the presence of heterogeneity (an I2 statistic in
excess of 30%), we plan to examine whether this heterogeneity can
be explained through our prespecified subgroup analyses. If these
analyses account for the heterogeneity, we would only present the
subgroup pooled effect estimates. If these subgroup analyses did
not explain the heterogeneity, we would present results narratively.
We intended to use fixed-effect meta-analysis and apply a conser-
vative I2 threshold to identify heterogeneity in this review to avoid
overweighting smaller studies. This is because we consider that the
heterogeneity observed in these behaviour change trials will pri-
marily be a result of differences in the content of the interventions
and differences in risk of bias.
’Summary of findings’ table
We created a ’Summary of Findings’ table of narrative results for
the following outcomes: objective measures of adherence to treat-
ment, combined CVD events (fatal and non-fatal events), adverse
events and cognitive outcomes. We used the five GRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence as it related to the studies that contributed data for
each outcome. We used methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011) using GRADE-
pro software (GRADEpro GTD 2015). We justified decisions to
downgrade the quality of studies using footnotes and made com-
ments to aid readers’ understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We had planned to conduct the following subgroup analyses for
the primary outcome of adherence to treatment if there had been
sufficient studies:
• income region (by World Bank income group) (World
Bank 2017);
• how text messages were developed (i.e. theory-based,
incorporating user views and based on evidence relating to
factors influencing behaviour-targeted versus other);
• intervention content (number behaviour change technique
employed coded according to the taxonomy developed by
Michie and colleagues (Michie 2015));
• delivery mechanisms (i.e. mobile phone messaging only,
mobile applications only, combined mobile phone messaging
and application, combined application and other).
Due to the limited number of studies, we were unable to conduct
subgroup analyses. Should more trials become available for future
updates of this review, we will re-examine the planned subgroup
analyses.
Sensitivity analysis
We planned to carry out a sensitivity analysis by only including
studies with low risk of bias. As we were unable to carry out a
meta-analysis, no sensitivity analysis was conducted.
R E S U L T S
Description of studies
Results of the search
The search of the databases retrieved 7287 records, and the search
of the clinical trial registers retrieved an additional 32 records. Af-
ter deduplication, we screened 4166 title and abstract records and
excluded 4115 records. We assessed 51 full texts and excluded 32
references (23 studies). Six studies (eight references) were identi-
fied as ongoing and four studies (11 references) were eligible for
inclusion. The flow diagram of search results is shown in Figure
1.
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Figure 1. Study flow diagram.
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Included studies
The Characteristics of included studies table presents details of
the design, methods, participants, intervention, comparison and
outcome measures for the studies included in this review. Four
studies were identified for inclusion, which were relatively hetero-
geneous with particular variation in terms of the nature (content
and delivery) of the intervention, and the population.
Participants
The sample sizes of included studies range from 110 (Logan 2012)
to 1372 (Bobrow 2016), with a total of 2429 participants across
all four included studies, of which 2031 participants completed
follow-up assessments.
Liu 2015 specified that participants must have had “no known
cardiovascular disease” as an inclusion criterion, and therefore in-
cluded 100% participants meeting the criteria for primary pre-
vention. The other included studies had a mix of participants:
Parraga-Martinez 2017 included 93% primary prevention partic-
ipants and Logan 2012 included at least 79% primary prevention
participants. Bobrow 2016 did not specifically report the propor-
tion of participants who met the criteria of primary prevention
in the published report; however, after contact with trial authors
they confirmed 78.3% of participants met the criteria for primary
prevention.
There was heterogeneity between trials in the proportion of par-
ticipants who were taking medication for the primary prevention
of CVD. Bobrow 2016 prescribed medication to all participants.
Logan 2012 included at least 89.1% of participants prescribed
medication (hypertensive drugs or lipid-lowering drugs or aspirin,
or a combination of these); and Parraga-Martinez 2017 stated that
68.1% of their sample had been prescribed lipid-lowering medica-
tion (but did not mention other types of CVD prevention drugs).
Liu 2015 did not report the proportion of participants prescribed
medication, but explicitly stated that the intervention targeted ad-
herence to medication among those on treatment.
The mean age of participants varied from 54.4 years (Bobrow
2016) to 62.9 years (Logan 2012). The proportion of women in
the trial samples ranged from 42% (Liu 2015) to 72% (Bobrow
2016).
Settings
All studies recruited from healthcare settings. Logan 2012 re-
cruited from the offices or clinics of physicians practicing in
metropolitan Toronto, Canada. Bobrow 2016 recruited from an
outpatient chronic disease service in a single, large, public sec-
tor clinic in Cape Town, South Africa. Parraga-Martinez 2017
recruited participants from primary care clinics in three health
districts of three Spanish autonomous communities. Liu 2015
recruited from a health management centre in a hospital in
Guangzhou, China.
Intervention
The content and delivery of the interventions varied across studies.
The intervention evaluated by Bobrow 2016 was specifically de-
signed to primarily focus onmedication adherence, with only a few
references to other lifestyle modifications such as diet and physical
exercise. In two trials, the interventions targeted a combination of
behaviours such as lifestyle modifications including healthy diet
and physical activity, alongside medication adherence for those
prescribed CVD medication (Liu 2015; Parraga-Martinez 2017).
The intervention tested by Logan 2012 was primarily a blood
pressure monitoring and feedback (via smartphone) intervention,
which could be considered to implicitly target adherence to treat-
ment as well as other health behaviours important for the control
blood pressure.
Bobrow 2016 delivered the intervention solely through mobile
phone text messages, and the intervention evaluated by Logan
2012 combined blood pressure monitoring with feedback mes-
sages delivered via smartphone. In the other studies, the interven-
tion included additional components alongside the mobile deliv-
ery component, such as written information and self-completion
cards for participants to record adherence to recommendations
(Parraga-Martinez 2017), and a computerised CVD risk evalua-
tion and a face-to-face counselling session (Liu 2015). Three of the
studies tested interventions which were delivered only to the par-
ticipant (Bobrow 2016; Liu 2015; Parraga-Martinez 2017), while
Logan 2012 evaluated an interventionwhich involved home blood
pressure monitoring and feedback to participants’ smartphones,
alongside an automated fax providing detailed information on the
participants’ status to their physicians on the day before their next
scheduled appointment.
Two studies involved potential users in developing the inter-
ventions (Bobrow 2016; Liu 2015), and none of the interven-
tions were developed based on a specific theory. The interven-
tions employed a minimum of three (Logan 2012) to a maxi-
mum of 16 (Bobrow 2016) behaviour change techniques. The
behaviour change techniques applied in the greatest number
of studies were: ’providing feedback on behaviour’ (Liu 2015;
Logan 2012; Parraga-Martinez 2017), ’providing information
about health consequences’ and ’emphasising the salience of con-
sequences’ (Bobrow 2016; Liu 2015; Parraga-Martinez 2017).
Three studies had a duration of the intervention of one year (
Bobrow 2016; Liu 2015; Logan 2012). One study had a follow-
up at two years, but it was unclear whether the intervention was
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delivered throughout the entire study period (Parraga-Martinez
2017).
Two studies had a control group that received standard care (Liu
2015; Parraga-Martinez 2017). The control group in Logan 2012
received the same home blood pressure monitoring equipment as
the intervention group and a booklet containing information on
themeasurement of blood pressure, treatment of hypertension and
goals of therapy. The control in group in Bobrow 2016 received
written information about hypertension and healthy living, and
only received text messages that were sent to all trial participants,
which were primarily related to trial participation.
Outcomes
All studies reported at least one objective measure related to med-
ication adherence. All four studies measured blood pressure, and
two studies measured cholesterol levels (LDL-C, HDL-C, TC)
(Liu 2015; Parraga-Martinez 2017). No studies reported outcome
data relating to combined CVD events (fatal or non-fatal). One
study reported adverse events, specifically adverse effects of statins
and intervention-related adverse events (Parraga-Martinez 2017).
Two studies reported indirect measures of adherence to treatment
(our secondary outcomes). One study included outcome data on
self-report adherence to lipid-lowering therapy, measured using
the Morisky-Green Test (Parraga-Martinez 2017). One trial in-
cluded self-reported adherence to medication measured using a
visual analogue scale, in addition to a measure of ’proportion of
days of medication covered’ (defined as the proportion of partic-
ipants with 80% or more days covered with blood pressure-low-
ering medication from prescribing and dispensing data routinely
recorded in the clinical record, pharmacy record and Chronic Dis-
pensing Unit record) (Bobrow 2016). This trial also included a
measure of quality of life (health status measured with the Eu-
roQol Group 5-Dimension Self-Report Questionnaire) and re-
ported deaths (including those caused by CVD events) occurring
during the trial (Bobrow 2016). Two trials reported data relating
to our process measures including satisfaction with the interven-
tion (Parraga-Martinez 2017), and adherence to the intervention
home blood pressure monitoring schedule (Logan 2012).
Funding
All four studies reported the source of funding; these were charita-
ble body and research council (Bobrow 2016), government body
and EU (Parraga-Martinez 2017), charitable body (Logan 2012),
and government body (Liu 2015).
Further information requested
Three of the trials identified for inclusion in this review included
participants who had, and participants who had not, been pre-
scribed CVD prevention medication (Liu 2015; Logan 2012;
Parraga-Martinez 2017). We contacted trial authors to request the
trial data for only these participants, but received no responses.
Therefore, we extracted primary outcome data of objective mea-
sures of medication adherence (e.g. blood pressure, LDL-C, etc.)
for thesemixed populations. We also contacted authors of one trial
for information relating to the proportion of participants who had
previously experienced a CVD event and received this informa-
tion (Bobrow 2016).
Excluded studies
See Characteristics of excluded studies table for details of excluded
studies.
Ongoing studies
We identified six ongoing studies (see Characteristics of ongoing
studies table). Three of these studies are being conducted in high-
income settings (Australia, 2000 participants (Redfern 2014);
USA, 4076 participants (Choudhry 2016); UK, 1010 participants
(Franssen 2017)). One study is being carried out in ’low resource
settings’ in Argentina (an upper- to middle-income country; ex-
pected 357 participants) (Gulayin 2017), one study in China, an
upper- to middle-income country (330 participants) (Xu 2017),
and one study in India (low- to middle-income country; 3702
participants) (Jha 2017).
Risk of bias in included studies
Details of the risk of bias assessments for each of the included stud-
ies are presented in the ’Risk of Bias’ tables in the Characteristics
of included studies table, and in Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three studies reported adequate random sequence generation and
were at low risk of bias for this domain (Bobrow 2016; Liu 2015;
Parraga-Martinez 2017). One study did not provide sufficient in-
formation and therefore was at unclear risk of bias for random
sequence generation (Logan 2012).
One study described their allocation concealment adequately and
was at low risk of bias in this domain (Bobrow 2016). The other
three studies did not provide sufficient information on their al-
location procedures and therefore were at unclear risk of bias for
allocation concealment (Liu 2015; Logan 2012; Parraga-Martinez
2017).
Blinding
In all four included studies the nature of the interventions pre-
cluded blinding of participants. However, blinding of person-
nel may have been possible. One study specifically stated that
personnel were not blinded to group assignment (Liu 2015).
Two studies stated that personnel were blinded (Bobrow 2016;
Parraga-Martinez 2017), and in one study it was not clear whether
personnel were blinded (Logan 2012). No trials were at low risk
of bias for blinding of both personnel and participants.
For the blinding of outcome assessment domain, one study pro-
vided sufficient detail relating to the blinding of outcome asses-
sors and the use of automated outcome measurements with data
transmitted directly to the trial database and as a result, was at low
risk of bias on this domain (Bobrow 2016). The remaining three
studies did not provide sufficient details for this domain and were
judged as being at unclear risk of bias (Liu 2015; Logan 2012;
Parraga-Martinez 2017).
Incomplete outcome data
Three studies had high rates of follow-up (85% or greater) with
no evidence of differential loss to follow-up and were at low risk
of bias on the incomplete outcome data domain (Bobrow 2016;
Logan 2012; Parraga-Martinez 2017). One study reported that
27.5% of participants did not attend for follow-up, and that they
differed from those who did attend for follow-up based on several
characteristics. The study also reported that these missing values
were likely to have little impact on the primary outcome based on
sensitivity analyses. However, it is unclear whether this may have
affected other outcomes, and so this study was judged as being at
unclear risk of bias on this domain (Liu 2015).
Selective reporting
One study reported outcomes as planned in their protocol, with
the exception of one outcome that was reported in protocol, but
not in the trial report (‘hypertension knowledge’). This trial be-
gan recruiting in June 2012, but details of the protocol were not
registered until December 2013, and so we cannot be certain as
to what was planned before the trial commenced. Therefore, we
judged this study at unclear risk of bias on the selective reporting
domain (Bobrow 2016). Two of the other trials also appeared to
have been registered after recruitment had begun, and therefore
were also judged at unclear risk of bias (Liu 2015; Logan 2012).
One study reported all outcomes as planned in the protocol with
the exception of cardiovascular events occurring during the study
period. This was considered an important outcome; however, it
was not clear whether this outcome was not reported because no
events occurred. Therefore, this trial was at unclear risk of bias on
this domain (Parraga-Martinez 2017).
Other potential sources of bias
All four trials were at low risk of ’other’ bias; all studies were funded
by government bodies, charitable bodies or research councils (
Bobrow 2016; Liu 2015; Logan 2012; Parraga-Martinez 2017).
Effects of interventions
See: Summary of findings for the main comparison Mobile
phone interventions compared to usual care for improving
adherence to medication prescribed for primary prevention of
cardiovascular disease
We did not pool results in a meta-analysis as the content and deliv-
ery mechanisms of the interventions were heterogeneous. The in-
tervention assessed byBobrow 2016was designed to focus onmed-
ication adherence and delivered solely through SMS. The inter-
vention tested byLogan 2012 was a bloodpressuremonitoring and
feedback (via smartphone) intervention. The Parraga-Martinez
2017 intervention targeted a combination of lifestyle modifica-
tions, alongside medication adherence for those prescribed CVD
medication and was delivered through text messages, written in-
formation pamphlets and self-completion cards for participants.
Finally, the intervention evaluated by Liu 2015 targeted healthy
lifestyle alongside treatment regimens with a multi-component
intervention comprising of text messages, a computerised CVD
risk evaluation and face-to-face counselling. Based on these dif-
ferences, we considered that pooling data from these trials would
not have been appropriate.
In generating the narrative forest plots, we also checked hetero-
geneity statistically (I2 greater than 90% for systolic blood pressure
(SBP) and diastolic blood pressure (DBP); I2 = 0% for TC; I2 =
73% for LDL-C; I2 = 0% for HDL-C). Based on these findings,
we considered pooling results from the two studies which reported
on TC andHDL outcomes; however, we still considered the inter-
ventions too distinct to warrant meaningful pooling (specifically,
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one intervention included face-to-face counselling (Liu 2015),
whereas the other consisted of written information and text mes-
sages (Parraga-Martinez 2017)).
We present results narratively, below, and in Analysis 1.1; Analysis
1.2; Analysis 1.3; Analysis 1.4; Analysis 1.5.
Primary outcomes
Objective measures of adherence to treatment
Cholesterol
Two trials reported LDL-C levels (Analysis 1.1), one of which
showed a reduction in LDL-C (MD in reduction: 9.20 mg/
dL, 95% CI 0.70 to 17.70, P = 0.034; 304 participants)
(Parraga-Martinez 2017), while the other demonstrated no evi-
dence of intervention effect on LDL-C (MD0.77 mg/dL, 95%CI
-4.64 to 6.18; 589 participants) (Liu 2015) (note: we converted
mmol/L cholesterol to mg/dL using a multiplier of 38.67 as rec-
ommended by Rugge 2011). We judged the evidence relating to
the intervention effect on LDL-C to be of low quality due to both
trials contributing to this comparison being at unclear risk of bias
across multiple domains, and the inconsistency in effect estimates
across studies.
These two trials also reported TC finding evidence of intervention
benefit (Analysis 1.2). Parraga-Martinez 2017 showed an MD in
the reduction of TC of 9.7 mg/dL (95% CI 0.30 to 19.10; P =
0.041) for the intervention compared with control group, and Liu
2015 recorded an MD in reduction of TC of 10.05 mg/dL (95%
CI -17.01 to -3.09).
Neither trial found evidence for an adverse effect on HDL-C (
Analysis 1.3) (MD1.16 mg/dL, 95%CI -1.55 to 3.87 (Liu 2015);
MD0.10mg/dL, 95%CI -2.60 to 2.80 (Parraga-Martinez 2017)).
Blood pressure
All four studies reported data for blood pressure, of which three
trials showed a beneficial intervention effect (Analysis 1.4; Analysis
1.5). We judged the evidence relating to SBP of low quality due
inconsistent outcome effects, and because all four of the trials
were at unclear risk of bias across multiple domains. Three trials
measuredDBP as an outcome and we considered this to constitute
low-quality evidence due to all three trials being at unclear risk of
bias across multiple domains, and inconsistency between studies
in the degree to which the outcome was affected.
Bobrow 2016 (1372 participants) reported a greater reduction in
mean SBP from baseline to 12-month follow-up in the interven-
tion group receiving information-only text messages compared
with the control group (MD -2.2 mmHg, 95% CI -4.4 to 0.00;
P = 0.046), but no difference between the intervention group re-
ceiving interactive text messaging and the control group (MD -1.6
mmHg, 95% CI -3.70 to 0.50, P = 0.16). Bobrow 2016 also pre-
sented the proportion of participants achieving SBP and DBP less
than 140/90 mmHg. They found evidence of benefit for both the
information-only text messaging intervention group (65% with
information-only text messaging versus 58% with control; odds
ratio (OR) 1.42, 95% CI 1.03 to 1.95; P = 0.033), and the inter-
active text messaging group (65% with interactive text messaging
versus 58% with control; OR 1.41, 95% 1.02 to 1.95; P = 0.038),
compared with the control group receiving usual care (Bobrow
2016).
Logan 2012 showed a greater reduction in SBP and DBP in the
intervention group comparedwith control group at 12months for:
24-hour blood pressure and daytime ambulatory blood pressure
(mean between-group difference in change (standard error (SE)):
24-hour SBP: -6.8 mmHg (SE 2.4); P = 0.005; 24-hour DBP: -
3.6 mmHg (SE 1.3); P = 0.006; daytime SBP: -7.10 mmHg (SE
2.3); P = 0.003; daytime DBP: -3.9 mmHg (SE 1.3) P = 0.003)).
However, there was at best only weak evidence of a benefit for
change in night-time blood pressure (SBP: -4.7mmHg (SE 2.8); P
= 0.098; DBP: -2.3 mmHg (SE 1.6); P = 0.16) (105 participants)
(Logan 2012).
Liu 2015 also found evidence of a beneficial intervention effect on
blood pressure at 12 months, with an MD between the interven-
tion and control group for SBP of -12.45 mmHg (95% CI -15.02
to -9.88) and for DBP of -12.23 (95% CI -14.03 to -10.43) (589
participants).
However, Parraga-Martinez 2017 found no evidence of a benefit
of their intervention for reducing blood pressure at two years,
with an MD in change of 0.83 mmHg (95% CI -2.67 to 4.33)
for SBP, and 1.64 mmHg (95% CI -0.55 to 3.83) for DBP (304
participants).
Heart rate
No studies reported heart rate.
Urinary 11-dehydrothromboxane B2
No studies reported urinary 11-dehydrothromboxane B.
Combined cardiovascular disease event (fatal or non-fatal
events)
No studies reported on combined CVD events.
Adverse effects
Based on two trials, we found low-quality evidence that the mo-
bile phone-based interventions under study did not lead to ad-
verse events. The evidence was of low quality due to the stud-
ies being at unclear risk of bias across multiple domains, and the
potential for imprecision in effect estimates resulting from the
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very low number of events. One study (1372 participants) re-
ported no adverse events attributable to the intervention (Bobrow
2016). The other study (304 participants) reported that there
were no differences between groups in experiencing adverse ef-
fects of statins (intervention group: seven events; control group:
10 events), and no participants reported intervention-related ad-
verse events (Parraga-Martinez 2017). The other two trials did not
report on adverse events (Liu 2015; Logan 2012).
Secondary outcomes
Indirect measures of adherence to treatment
An overview of the trial results relating to indirect measures of
medication adherence is presented in Table 1. Bobrow 2016 (1372
participants) presented 12-month outcome data for the median
difference in the proportion of days covered by dispensed medi-
cation, finding evidence of a modest benefit for both the informa-
tion-only text messaging intervention group (83.3% with inter-
vention versus 79.2% with control; median difference 5.2, quar-
tiles 1-3: 1.5 to 8.9; P = 0.006), and the interactive text messaging
group (83.3% with intervention versus 79.2% with control; me-
dian difference: 3.8, quartiles 1-3: 0.03 to 7.6; P = 0.048), com-
pared with the control group receiving usual care (Bobrow 2016).
There were similar results for the outcome of achieving 80% or
more days covered (information-only text messaging group versus
control: OR 1.86, 95% CI 1.39 to 2.49; P < 0.001; interactive
text messaging group versus control: OR 1.60, 95% CI 1.20 to
2.16; P = 0.002) (it is not clear how the underlying proportions
compared as the authors did not report the proportion achieving
80% or more days covered for the control group). However, there
was no evidence of benefit for the outcome of self-reported med-
ication adherence (information-only text messaging group versus
control: median difference 0.04, quartiles 1-3: -0.1 to 0.2; P =
0.70; interactive text messaging group versus control: median dif-
ference 0.02, quartiles 1-3: -0.2 to 0.2, P = 0.80).
Parraga-Martinez 2017 also reported outcome data for self-re-
ported adherence to treatment (specifically to lipid-lowering ther-
apy) measured using the Morisky-Green Test, among those par-
ticipants prescribed lipid-lowering therapy. This study found ev-
idence of benefit for the outcome of proportion of participants
reporting adherence at two years’ postrandomisation (77.2% with
intervention versus 64.1% with control; P = 0.029, 220 partici-
pants).
Fatal cardiovascular events
Bobrow 2016 (1372participants) reported that twoparticipants in
the information-only text messaging group died due to ischaemic
heart disease, two participants in the interactive text messaging
group died due to congestive cardiac failure and there were no
deaths in the control group known to be due to CVD. There were
slightly more participants in the usual care arm who were lost to
follow-up due to the reason of ’lost contact’ (14 participants), com-
pared to the information SMS arm (seven participants), and the
interactive SMS arm (seven participants). Therefore, it is possible
that this differential lost to follow-up due to lost contact could
have underestimated deaths, including those due to CVD, in the
usual care arm.
Non-fatal cardiovascular events
No studies reported non-fatal cardiovascular events.
Health-related quality of life assessed using validated
instruments
Bobrow 2016 reported the median difference in quality of life as
measured by the Euro-Qol 5-Dimension Index, finding no effect
of the information-only text messages (median difference 0.01,
quartiles 1-3: -0.01 to 0.02; P = 0.50) or the interactive text mes-
sages (median difference: 0.003, quartiles 1-3: -0.02 to 0.02; P =
0.73) compared with the control group.
Cognitive outcomes
Bobrow 2016 measured satisfaction with treatment and found no
evidence of difference between intervention arms and control arm
(information-only text messaging group versus control: median
difference 0, quartiles 1-3: -0.3 to 0.3; P > 0.99; interactive text
messaging group versus control: median difference 0, quartiles 1-
3: -0.3 to 0.3; P > 0.99).
Costs
No studies reported costs.
Process measures
Parraga-Martinez 2017 recorded satisfaction with the interven-
tion, finding that 90.8% (95% CI 85.9 to 95.7) of the 155 inter-
vention group participants reported being satisfied or very satisfied
with the intervention at two years’ postrandomisation. Logan 2012
recorded a 65.4% (standard deviation 30) adherence rate to the
home blood pressure measurement schedule (taking a minimum
of eight readings per weeks) in the intervention group. Bobrow
2016 reported that 50% of participants allocated to the interac-
tive SMS intervention arm responded to messaging. No studies
reported on other process indicators such as measures relating to
the proportion of intervention received/used.
D I S C U S S I O N
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Summary of main results
This review provided low-quality evidence regarding the effects
of adherence interventions delivered by mobile phone, with some
trials reporting small benefits and other reporting no benefits.
There was low-quality evidence that the interventions did not
cause harm. In our review, we identified four trials, none of which
were at low risk of bias. One trial evaluated an intervention target-
ing medication adherence via text messaging and one trial assessed
a blood pressure monitoring system which delivered feedback to
participants via smartphone messaging. The remaining two tri-
als were of interventions targeting healthy lifestyle modifications
more generally, including adherence to medication, one of which
was delivered through text messages, written information pam-
phlets and self-completion cards for participants, and the other
through a combination of text messages, a computerised CVD risk
evaluation and face-to-face counselling. Due to these differences
in content and delivery of the interventions, we did not pool re-
sults in a meta-analysis.
We considered the body of evidence relating to the effect of mobile
phone-based interventions to be of low quality for outcomes relat-
ing to blood pressure and cholesterol due to the trials being at high
risk of bias across multiple domains, and inconsistent outcome ef-
fects. The trial of the text messaging-based intervention targeting
adherence showed a small reduction in SBP for the intervention
arm which delivered information-only text messages, but no evi-
dence of a benefit for the second intervention arm that provided
interactivity in addition to the information-based text messages.
Bobrow 2016 reported that only 50% of participants allocated
to the interactive SMS intervention arm responded to messages,
which may be indicative of relatively low engagement with this
feature. Both arms demonstrated an increase in the proportion of
participants achieving the recommended threshold for SBP and
DBP, with a modest risk difference between the intervention and
control groups of 7% (Bobrow 2016). One of two indirect mea-
sures of adherence also showed improvements and there was no
difference in CVD-related deaths, health-related quality of life or
cognitive outcomes (satisfaction with treatment) (Bobrow 2016).
The study examining the effect of blood pressure monitoring, and
messaging via smartphone, reported a modest intervention benefit
on four of their six outcome measures of blood pressure (Logan
2012). There was mixed evidence of benefit in two trials targeting
medication adherence alongside other lifestyle advice. Liu 2015
reported benefits in SBP and DBP, but Parraga-Martinez 2017
reported no such effects. Both trials reported a beneficial effect of
their intervention on lowering TC (Liu 2015; Parraga-Martinez
2017); however, only Parraga-Martinez 2017 found an effect on
LDL-C. Only one trial included an indirect measure of adher-
ence reporting a benefit in self-reported medication adherence
(Parraga-Martinez 2017). In both of these trials the contribution
of increased adherence to the reductions in cholesterol and blood
pressure reported was unclear due to their inclusion of a mix of
participants who had and had not been prescribed CVD medica-
tion (Liu 2015; Parraga-Martinez 2017).
Two trials reported on adverse events and provided low-quality
evidence that the interventions did not cause harm (Bobrow 2016;
Parraga-Martinez 2017).
Overall completeness and applicability of
evidence
The generalisability of this review was limited by the small num-
ber of trials identified for inclusion. Given that one of our in-
clusion criteria was trials having a minimum of one-year follow-
up, we can be confident that our results are applicable to longer-
term, sustained medication adherence behaviours and outcomes.
No studies reported on non-fatal cardiovascular events, meaning
we were unable to establish whether the modest benefits observed
in individual trials for cholesterol and blood pressure translated
into such patient-relevant outcomes. Two studies were conducted
in high-income settings and two in upper- to middle-income set-
tings, meaning that the applicability of these results to other set-
tings including low-income settings is unclear. Four of the six
ongoing studies identified are being carried out in high-income
countries, however, one trial is being conducted in ’low resource
settings’ in Argentina, and one in a low- to middle-income county
(India), which may provide greater information on the applicabil-
ity of results across settings (Gulayin 2017).
Quality of the evidence
Using GRADE methodology we assessed the quality of the evi-
dence for our narrative synthesis of objective outcomes of med-
ication adherence (LDL-C, SBP and DBP), cognitive outcomes
and adverse events. The evidence was of low quality across all out-
comes. The quality of the evidence relating to objective outcomes
of medication adherence were downgraded one level as a result
of inconsistency in effect estimates which spanned both clinically
meaningful improvements and null effects. The quality of the ev-
idence relating to all five outcomes considered were downgraded
one level because none of the included studies were at low risk
of bias. Three of the four studies were at unclear risk of bias on
at least four of the domains, indicating poor quality of report-
ing of the trial methods in these studies which limited our ability
to make clear judgements about the level of risk of bias. Finally,
the evidence relating to the cognitive outcome of satisfaction with
treatment was also downgraded for indirectness, because this was
based on one trial conducted in a single setting.
Two trials of interventions targeting broader lifestyle modifica-
tions, including medication adherence, included a mixture of par-
ticipants who had and had not been prescribed CVD prevention
medication, and therefore, in both of these trials the contribution
of increased adherence to the reductions in cholesterol and blood
pressure reported was unclear (Liu 2015; Parraga-Martinez 2017).
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Potential biases in the review process
We were limited in the outcome data we could extract due to our
inability to procure further information and data for subsets of
specific participants in the included trials from the study authors.
It is unclear whether the additional data would have altered the
overall findings of this review. Our inability to conduct a meta-
analysis means that this review cannot benefit from examining
pooled effect estimates based on larger sample sizes than the in-
dividual trials. Furthermore, publication bias, whereby trials with
positive findings are more likely to be published, may have biased
the selection of included studies in this review. However, efforts
were made to overcome this through searching clinical trial reg-
istries for prospectively registered trials. The decision was taken to
only include trials with a minimum of one-year follow-up in or-
der that results were applicable to longer-term sustained behaviour
change in adherence, which would therefore be more important
in improving health status. This means that we are unable to com-
ment on the effectiveness of mobile phone-based interventions for
short-term adherence to medication prescribed for the primary
prevention of CVD.
Agreements and disagreements with other
studies or reviews
Our findings of mixed evidence of the effects of mobile phone-
delivered interventions to increase adherence to medication pre-
scribed for the primary prevention of CVD and no reported harms
are consistent with those of a Cochrane Review examining the ef-
fectiveness of text-messaging interventions to improve adherence
to medication prescribed for the secondary prevention of CVD
(Adler 2017). These findings are broadly consistent with system-
atic reviews concerned with mhealth interventions to improve
medication adherence across conditions, although these reviews
included short-term studies and non-RCT designs, which are sub-
ject to bias (Anglada-Martinez 2015; Park 2014b). One system-
atic review examining RCTs of monitoring and messaging inter-
ventions targeting medication adherence for the management of
type 2 diabetes found no evidence for an improvement in medica-
tion adherence in their pooled meta-analyses of five trials (Farmer
2016). Our finding that one intervention delivered by text mes-
saging alone reported small benefits, some of which achieved sta-
tistical significance, is consistent with the findings from trials em-
ploying SMS alone targeting adherence to HIVmedication which
also report small benefits of borderline clinical and statistical sig-
nificance (da Costa 2012; Orrell 2015; Pop-Eleches 2011; Sabin
2015). The reported benefits of the monitoring and SMS inter-
vention is consistent with themodest benefits of monitoring inter-
ventions in general (Carrasco 2008; Lim 2011; McKinstry 2013;
Yoo 2009). The small or modest benefits reported may reflect the
challenges involved in improving adherence, and overall inconclu-
sive findings relating to adherence interventions in general, which
have previously been noted in a Cochrane Review of all adherence
interventions (Nieuwlaat 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results are based on four trials, none of which was considered
to be at low risk of bias. Therefore, given the low quality of the
evidence presented, the implications for practice are limited. From
the four studies reporting on change in systolic blood pressure
as an outcome, effects ranged from reductions of 12.5 mmHg to
increases of 0.83 mmHg, with two studies exceeding a 5 mmHg
mean reduction (a 5 mmHg reduction in systolic blood pressure
is generally considered to result in clinically important reductions
in the relative risk of stroke and coronary heart disease events
(Collins 1990)). The delivery of mobile phone-based interven-
tions is inexpensive and previous analyses of such interventions in
other fields have demonstrated cost-effectiveness (Guerriero 2013;
Lester 2010). If comparable effectiveness results are replicated in
other high-quality trials, it would be useful to consider cost-effec-
tiveness of the intervention, as if shown to be cost-effective, the
small benefits achieved at low cost might be important if achieved
across whole populations. The Cholesterol Treatment Trialists’
Collaboration estimates that for each 1 mmol/L (38.67 mg/dL)
reduction in low-density lipoprotein cholesterol (LDL-C) there is
a consistent 20% relative risk reduction for major vascular events
regardless of baseline risk (CTT 2012). The two trials measuring
LDL-C as an outcome reported effects ranging from a 9.2 mg/dL
reduction to a 0.77 mg/dL increase, meaning that even the larger
of these effects would have a small impact on clinical outcomes.
Implications for research
The intervention delivered by SMS alone which resulted in small
benefits in adherence was developedwith input fromusers. The in-
tervention targetedmany of the barriers to adherence, whichmight
conceivably be addressed using SMS, employing a wide range of
behavioural change techniques. Nonetheless, the finding of only
small benefit is consistent with results of adherence interventions
delivered by SMS for secondary prevention of CVD, HIV medi-
cation and diabetes (Adler 2017; Anglada-Martinez 2015; Farmer
2016). It is possible that the intervention delivered by SMS has
small effects because some behaviour change techniques may not
be effective when adapted for delivery by SMS. Adherence is in-
fluenced by a wide range of service and social factors, in additional
to the individual level factors like knowledge motivation and skills
which might be targeted using short written messages (DiMatteo
2004; Julius 2009; Kardas 2013; Nieuwlaat 2014; Pound 2005;
Vermeire 2001). Future adherence interventions should consider
targeting a broader range of factors influencing adherence. Given
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the importance of healthcare providers in influencing medication
use and altering medication if unacceptable adverse effects occur,
interventions may require integration with services to result in
clinically important benefits for individuals. Furthermore, future
trials should consider targeting people most at risk of poor adher-
ence and excluding those known to be adherent.
Finally, given the heterogeneity that exists between behaviour
change interventions, we believe there is a case to be made that
individual high-quality adequately powered trials could provide
higher quality evidence relating to the effectiveness of such inter-
ventions, compared with evidence based on attempts to pool mul-
tiple smaller, lower-quality and potentially heterogeneous trials.
Several of the ongoing trials identified have large sample sizes, and
so if adequately powered and at low risk of bias, these studies may
provide high-quality and more precise estimates of the effect of
adherence interventions delivered by mobile phone.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bobrow 2016
Methods Design: 3-arm, parallel RCT
Setting: outpatient chronic disease services in a public sector clinic, Cape Town, South
Africa
Duration of study: 12 months
Participants Number randomised: 1372; group 1 (control): 457; group 2 (informational SMS): 457;
group 3 (interactive SMS): 458
Number lost to follow-up/withdrawn: 176; group 1: 61 (reasons: 3 died; 2 pregnant;
14 lost contact; 12 moved; 25 unable to attend; 5 reason not given); group 2: 51 (reasons:
7 died; 2 pregnant; 7 lost contact; 11 moved; 23 unable to attend; 1 reason not given)
; group 3: 64 (reasons: 7 died; 5 pregnant; 2 participant decision; 7 lost contact; 14
moved; 29 unable to attend)
Number analysed: 1372; group 1: 457; group 2: 457; group 3: 458 (intention-to-treat
analysis using all data available)
Mean age in years (SD): group 1: 54.7 (SD 11.6); group 2: 53.9 (SD 11.2); group 3:
54.2 (SD 11.6)
Age range: not stated
Gender (% women): group 1: 72; group 2: 72; group 3: 72
Proportion meeting criteria of ’primary prevention’: 78.3% (unpublished informa-
tion received from authors)
Proportion prescribed medication for prevention of CVD: 100%; prescribed BP-
lowering medication was an inclusion criterion
Inclusion criteria: aged ≥ 21 years, diagnosed with hypertension by a clinician using
local guidelines, prescribed BP-lowering medication, and with SBP < 220 mmHg and a
DBP < 120 mmHg at enrolment. Eligible participants were attending the primary care
clinic, resided in 1 of the 2 study communities and had regular access to a mobile phone
(and were able to send SMS text messages or could do so with help of a relative)
Study enrolled only 1 member per household.
Exclusion criteria: requiring specialist care for hypertension at a hospital (in secondary
care), women who self-reported being pregnant or within 3 months postpartum, and
people with very high BPs (SBP > 220mmHg orDBP > 120mmHg) who had symptoms
suggestive of a hypertensive emergency or were otherwise acutely unwell (who were
directly referred to the appropriate clinical service)
Interventions Intervention: all participants received written information about hypertension and con-
tinued to receive care from the clinic
Group 2: ’informational SMS texting:’ participants received: text messages to motivate
collecting and taking medicines and to provide education about hypertension and its
treatment. The messages were designed to address a range of common issues with adher-
ence to and persistence with treatment. Additional reminders were sent when medicines
were ready for collection or for scheduled clinic appointments
Group 3: ’interactive SMS texting’ group: participants received: the same messages as
the information-only group but could also respond to selected messages using free-to-
user “please call me” requests. These generated an automated series of responses from the
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Bobrow 2016 (Continued)
text message delivery system offering trial participants a number of options, including
cancelling or changing an appointment and changing the timing and language of the text
messages. The intervention was specifically designed to primarily focus on medication
adherence, with only a few references other lifestyle modifications such as diet and
physical exercise
Comparison: control group (group 1) received written information about hypertension
and healthy living and continued to receive care from the clinic. The control group only
received the texts sent to all trial participants, which were sent no more frequently than
1 text every 4 weeks. The messages were a welcome text, a text confirming enrolment, a
text on a birthday and other text messages about participation in the trial
How intervention was developed: the researchers iteratively designed, developed and
tested 2 SMS text messaging-based interventions with clinical staff and participants with
high BP working and living in low-income communities around Cape Town
Behaviour change technique(s) employed: 16 in total: problem solving; goal setting;
action planning; review of behavioural goals; behavioural contract; commitment; general
social support; practical social support; emotional social support; providing information
about health consequences; emphasising salience of consequences; anticipated regret;
behavioural rehearsal; behavioural substitution; habit formation; generalisation of target
behaviour
Personalised intervention: some texts were personalised to include participants’ first or
chose name. Information provided not personalised, but reminders of whenmedications
were available for collection and dates of next appointment indicates some personalisa-
tion. Additionally, the ’interactive SMS texting’ group (group 3) could request further
interactions
Frequency andduration of intervention receipt:messages sent weekly at a time selected
by participant. Intervention duration: 12 months
Outcomes Primary outcomes: SBP (mean); proportion of participants achieving a mean SBP <
140 mmHg and a mean DBP < 90 mmHg. Measured at 12 months’ postrandomisation
Secondary outcomes:medication adherence: ’proportion of days ofmedication covered’
(the proportionof participantswith≥ 80%of days coveredwithBP-loweringmedication
from prescribing and dispensing data routinely recorded in the clinical record, pharmacy
record and Chronic Dispensing Unit record); self-reported adherence to medication
using a visual analogue scale (score range, 5-10); health statusmeasuredwith the EuroQol
Group5-DimensionSelf-ReportQuestionnaire; self-reported satisfactionwith treatment
Process outcomes: knowledge about hypertension was measured, but not reported in
trial paper
Adverse events: protocol stated recording of those which might reasonably occur as
a consequence of the trial and adverse events that might be reasonably related to text
messaging including hand or finger pain, or involvement in an accident as a result of
sending or receiving a text
Notes Funding source: trial supported by the Oxford Centre of Excellence in Medical Engi-
neering funded by the Wellcome Trust and the Engineering and Physical Sciences Re-
searchCouncil. Dr Farmer is a seniorNIHR investigator, andDrs Farmer andTarassenko
are supported by funding from the NIHR Oxford Biomedical Research Center. The
funders had no role in study design, data collection and analysis, decision to publish or
preparation of the manuscript
Conflicts of interest: none declared
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Bobrow 2016 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “participants are randomised us-
ing a secure, remote, web-based computer
schedule within one week of recruitment [.
..] minimisation procedure [was] overseen
by an independent statistician.”
Allocation concealment (selection bias) Low risk Quote: “A software algorithm assigned
participants independently of the research
team.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants cannot be blinded due to na-
ture of intervention. However, “research
staff and clinic staff remain blind to the al-
located treatment group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Researchers and clinicians were
not aware of randomization assignment,
were trained not to ask patients about the
content of messages.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 87% follow-up rate, no evidence of differ-
ential follow-up, ITT analysis accounting
for missing data
Selective reporting (reporting bias) Unclear risk Outcomes reported as planned in protocol
(the only outcome reported in protocol that
was not reported in trial paper was ’hyper-
tension’ knowledge).However, this trial be-
gan recruiting in June 2012, but details of
the protocol were not registered until De-
cember 2013. Therefore, we could not be
certain what was planned before the trial
commenced
Other bias Low risk Funded by charity and research council.
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Liu 2015
Methods Design: 2-arm, parallel RCT
Setting: employees of work units (places of employment) who had been allocated to have
a medical examination at the health management centre of a hospital in Guangzhou,
China
Duration of study: 1 year
Participants Number randomised: 589; intervention: 238; control: 351
Number lost to follow-up/withdrawn: 162 (intervention: 75; reasons: not stated; con-
trol: 87; reasons: not stated)
Number analysed: 589, intervention: 238; control: 351 (missing data imputed)
Mean age in years (SD): intervention: 58.7 (SD 8.9), control: 61.8 (SD 8.8)
Age range: not stated
Gender (% women): intervention: 41.6; control: 41.9
Proportionmeeting criteria of ’primaryprevention’:100%; inclusion criteria included
having no known CVD.
Proportion prescribed medication for prevention of CVD: not reported. Authors
contacted for further information and the data for those prescribed medication, but we
received no response
Inclusion criteria: aged 45-75 years, without known CVD, willing to participate in the
programme
Exclusion criteria: history of mental abnormalities; difficulty in communication, such
as reading or answering the questionnaire; unable to understand the aim of this study;
currently participating in another clinical trial or had done so within the previous 6
months
Interventions Intervention: participants in the intervention group received a computerised CVD risk
evaluation, follow-up phone calls and text messages targeting reducing the CVD risk
in addition to the usual medical examination. The plan included guidance of healthy
lifestyle, improvement targets for risk factors and drug treatment goals for those being
treated. Participants also received a 15-minute face-to-face counselling with a trained
field health worker when they enrolled to the study
Comparison: participants in the control group received the annual medical examination
with a usual medical report. This report included the results of physical examination and
the normal values of the indicators
How intervention was developed: authors stated, “we developed a mobile phone-
based intervention program to reduce CVD risk, which was assessed by the Chinese
cardiovascular disease risk assessment method.”
Behaviour change technique(s) employed: 7 in total: problem solving; commitment;
feedback on behaviour; instruction on how to performbehaviour; providing information
about health consequences; emphasising salience of consequences
Personalised intervention: yes; individualised electronic health prescription software
(IEHPS) calculated participants’ overall risk of CVD in the next 10 years which informed
participants individualised intervention plan
Frequency and duration of intervention receipt: frequency of phone calls and text
messages depended on participants’ individual 10-year CVD risk. Phone calls (length 5-
8 minutes) ranged from twice a month to once a week, text messages ranged from once
a month to once a week. Duration: 1 year
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Liu 2015 (Continued)
Outcomes Primary outcomes: LDL-C, TC, HDL-C, SBP, DBP. All measured at 1-year postran-
domisation. Medical outcomes were presented for entire sample, which included partici-
pants not taking medication for primary prevention of CVD.We have contacted authors
requested trial data for those participants taking medication for primary prevention of
CVD
Secondary outcomes: none reported.
Process outcomes: none recorded.
Adverse events: none recorded.
Notes Funding source: Guangdong Provincial Department of Science and Technology (grant
No. 2009A030301003) and the Bureau of Health of Guangzhou Municipality (grant
No. 2008-ZDa-05)
Conflicts of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was done via
a computerized procedure.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither participants nor investiga-
tors were masked to group assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessments bymedical students; not stated
whether they were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “27.5% of participants failed to at-
tend the follow-up. Participants who were
lost to follow-up were more likely to be
younger, male, current smokers and have
a higher level of TC than those who were
included in the follow-up.”
Selective reporting (reporting bias) Unclear risk Protocol not found. Trial appeared to
have been registered after recruitment be-
gan in October 2012 (www.chictr.org.cn/
hvshowproject.aspx?id=7953)
Other bias Low risk Funded by government body
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Methods Design: 2-arm, parallel RCT
Setting: clinics in metropolitan Toronto, Canada
Duration of study: 1 year
Participants Number randomised: 110; intervention: 55; control: 55
Number lost to follow-up/withdrawn: 6; intervention group: 2 (reasons: 2 refused BP
assessment); control group: 4 (reasons: 3 refused BP assessment; 1 died)
Number analysed: 105; intervention group: 54; control group: 51
Mean age in years (SD): intervention group: 62.7 (SD 7.8); control group: 63.1 (SD
9.0)
Age range: not stated
Gender (% women): intervention group: 51; control group: 38
Proportionmeeting criteria of ’primary prevention’: intervention group: 79.9%; con-
trol group: 78.1%. Paper reported proportion with prior CVD event by CVD event,
possible that the same participants had > 1 type of event, therefore percentage stated was
minimum estimate of participants meeting criteria of primary prevention
Proportion prescribed medication for prevention of CVD: hypertensive drugs: inter-
vention group: 89.1%; control group: 89.1%; lipid-lowering drugs: intervention group:
69.1%; control group: 70.9%; aspirin: intervention group: 54.5%; control group: 58.
2%. We contacted authors to request data for those prescribed medication, but had no
response
Inclusion criteria: aged ≥ 30 years, with diabetes mellitus, with uncontrolled systolic
hypertension, defined as a mean daytime SBP of ≥ 130 mmHg on ambulatory BP
monitoring
Exclusion criteria: those with severe or end-stage organ disease (liver, kidney, heart and
lung), history of diabetic ketoacidosis, any illness with expected survival < 1 year, severe
cognitive impairment, mental illness or disability, clinically significant cardiac arrhyth-
mia, symptomatic orthostatic hypotension, or were pregnant, unsuitable for participa-
tion in the opinion of their primary care physician or not fluent in English
Interventions Intervention: participants received custom software application running on a Black-
Berry smartphone (Research In Motion, Inc, Waterloo, ON, Canada) that was paired
with a Bluetooth-enabled home BP monitoring device. BP readings were automatically
transmitted by the smartphone to application servers, which processed the information
for trends and applied decisions rules. The reporting and alerting component of the
system sent a self-care message to the screen of the participant’s smartphone immediately
after each reading. Messages related to the control of hypertension were based on care
paths defined by running means of transmitted readings. On the day before the clinic
visit to their physician, participants called a dedicated telephone number to initiate the
automated process to fax a 1-page participant summary report to their physician. Self-
care support participants were taught how to use the telemonitoring system, review past
readings on their smartphone and the study-specific website (these activities were op-
tional), and generate a 1-page participant summary report. They were instructed to take
their smartphone to all doctor visits
Comparison: participants in both groups were taught how tomeasure their BP correctly,
instructed to measure their BP 2 days per week twice in the morning and twice in the
evening, provided with a validated home BP monitoring device with appropriate-sized
upper arm cuff, and given a booklet with detailed information on the self-measurement
of BP, treatment of hypertension and goals of therapy. Their primary care physician was
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given an outline of the study’s objectives and BP treatment goal, asked to provide relevant
medical information and given a copy of the 24-hour ambulatory BP monitoring report.
In both groups, treatment decisions, including medication adjustments and changes in
lifestyle, were made by the participant’s primary care physician. The control group did
not received feedback via smartphone
How intervention was developed: system developed using an iterative process based
on feedback from users. A pilot study was undertaken to assess the system’s effectiveness
in improving BP control in people with diabetes with uncontrolled hypertension, its
acceptability to users and the reliability of home BP measurements
Behaviour change technique(s) employed: 3 in total: feedback on behaviour, self-
monitoring, prompts
Personalised intervention: information sent via smartphone was personalised in that it
was based on participants’ own BP readings
Frequency and duration of intervention receipt: participants were instructed to mea-
sure their BP 2 days per week twice in the morning and twice in the evening, and a self-
care message was sent to the participant’s smartphone immediately after each reading.
Duration: 1 year
Outcomes Primary outcomes: mean ambulatory SBP and DBP; proportion achieving guideline
recommended target of BP < 130/80 mmHg. Measured at 1 year’ postrandomisation.
The medical outcomes are presented for entire sample, which included participants not
taking medication for primary prevention of CVD. We contacted authors requesting
trial data for those participants taking medication for primary prevention of CVD, but
had no response
Secondary outcomes: none reported.
Process outcomes: adherence rate with home BP measurement schedule (% taking a
minimum of 8 readings per week)
Adverse events: none recorded.
Notes Funding source: the Heart and Stroke Foundation of Ontario (ESA 5970) was the sole
source of funding for this project and was not involved in any aspect of the study
Conflicts of interest: JAC received funding from Research In Motion, Inc. (makers
of the Blackberry mobile telephones) through the National Science and Engineering
Research Council Strategic Network Grant Program. PGR received reimbursement of
expenses from Research In Motion, Inc., to attend a healthcare advisory meeting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Group allocation schedule was
based on blocks of 4 and 6 patients ran-
domly arranged and administered by a per-
son not directly involved in the study.”
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants cannot be blinded due to na-
ture of intervention. Unclear whether per-
sonnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 90% follow-up, no evidence of differen-
tial follow-up
Selective reporting (reporting bias) Unclear risk According to trial registry entry (clinical-
trials.gov/ct2/show/NCT00717665), the
trial was registered after the first participant
was randomised
Other bias Low risk Funded by charitable body
Parraga-Martinez 2017
Methods Design: 2-arm, parallel RCT
Setting: primary care clinics in 3 health districts of 3 Spanish autonomous communities:
Castile-La Mancha (Albacete), Aragon (Zaragoza) and Galicia (Vigo), Spain
Duration of study: 24 months
Participants Number randomised: 358; intervention group: 179; control group: 179
Number lost to follow-up/withdrawn: 54 (intervention group: 24 (reasons: 14 with-
drew consent; 2 discontinued due to change of residence; 2 discontinued due to disease;
1 discontinued due to other reasons; 5 protocol violation); control group: 30 (reasons:
17 withdrew consent; 1 discontinued due to change of residence; 3 discontinued due to
disease; 3 discontinued due to other reasons; 6 protocol violation)
Number analysed: 304; intervention group: 155; control group: 149
Mean age in years (SD): intervention group: 58.9 (SD 10.4); control group: 59.3 (SD
8.4)
Age range: not stated
Gender (% women): intervention group: 56.1; control group: 53.7
Proportionmeeting criteria of ’primary prevention’: total: 93.1%; intervention group:
91.0%; control group: 95.3%
Proportion prescribed medication for prevention of CVD: only statin use stated;
total 68.1%; intervention group: 64.5%; control group: 71.8%). We contacted authors
requesting trial data for those participants taking medication for primary prevention of
CVD, but had no response
Inclusion criteria: aged ≥18 years, previously diagnosed with defined hypercholestero-
laemia (TC ≥ 250 mg/dL) who were receiving standard treatment (drug-based or not)
and attending the participating centres
Exclusion criteria:unable to undergo follow-upduring the intervention (due to illiteracy
or lack of a mobile telephone), had a physical disability impeding participation, or had
a severe organic or psychiatric chronic disease precluding follow-up
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Interventions Intervention: participants received the following: written information on the disease and
its treatment (provided at each visit); mobile telephone text messages with summaries
of recommendations, reminders of dates of next appointments and notifications of new
appointments if any previous ones were missed (during between-visit periods); and self-
completed registration cards on adherence to recommendations (during the entire follow-
up). Intervention group also received the standard recommendations of the European
clinical practice guidelines for treatment of hypercholesterolaemia and cardiovascular
risk. The intervention targeted lifestylemodifications, including healthy diet andphysical
activity, alongside medication adherence for those prescribed CVD medication
Comparison: participants received the standard recommendations of the European clin-
ical practice guidelines for treatment of hypercholesterolaemia and CVR
How intervention was developed: not stated
Behaviour change technique(s) employed: 6 in total: feedback on behaviour; self-
monitoring; instruction on how to perform behaviour; providing information about
health consequences; emphasising salience of consequences; prompts
Personalised intervention: information provided not personalised, but reminders of
dates of next appointment indicates some personalisation
Frequency and duration of intervention receipt: the disease treatment reminders were
sent every 15 days, whereas the attendance reminders for upcoming or missed appoint-
ments were sent according to the follow-up date. Intervention duration: 24 months (al-
though not clear if this relates to all components of the intervention)
Outcomes Primary outcomes: LDL-C; TC; HDL-C; SBP; DBP. All measured 2 years’ postran-
domisation. The medical outcomes are presented for entire sample, which includes par-
ticipants not taking medication for primary prevention of CVD. We contacted authors
requesting trial data for those participants taking medication for primary prevention of
CVD, but had no response. Cardiovascular events in the observation period stated in
protocol, but not reported in trial results
Secondary outcomes: self-report adherence to lipid-lowering therapy (measured using
the Morisky-Green Test) at 2 years’ postrandomisation
Process outcomes: satisfaction with intervention (measured using a Likert scale satis-
faction questionnaire) at 2 years’ postrandomisation
Adverse events: adverse effects of statins; intervention-related adverse effects
Notes Funding source: funding from the Instituto de Salud Carlos III and the Health Re-
search Project Subprogram of the European Regional Development Fund (PI12/01955)
, resolution 20 December 2012
Conflicts of interest: none declared.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “participant randomization was
centrally performed according to health
care region (Efron randomization) by a re-
searcher who was not involved in the inter-
views or analysis.”
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Allocation concealment (selection bias) Unclear risk Allocation of area was concealed; how-
ever, once areas were allocated, participants
were allocated according to their area. It is
not clear whether recruiting staff may have
known to which area the participants be-
longed and therefore to which group they
would be randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants cannot be blinded due to na-
ture of intervention. However, report states
“results were evaluated in a blinded man-
ner.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated whether outcome measure-
ments were taken by blinded personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up rate of 85% and no evidence of
differential follow-up
Selective reporting (reporting bias) Unclear risk Outcomes reported as planned in protocol,
with the exception of cardiovascular events
occurring in the trial period which were
stated in protocol but not included in trial
report
Other bias Low risk Funding from government body
BP: blood pressure; CVD: cardiovascular disease; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; ITT:
intention to treat; LDL-C: low-density lipoprotein cholesterol; NIHR: National Institute for Health Research; RCT: randomised
controlled trial; SBP: systolic blood pressure; SD: standard deviation; SMS: short messaging service; TC: total cholesterol.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bosworth 2007 No mobile phone specific intervention delivery
Bove 2011 No mobile phone-specific intervention delivery
Broekhuizen 2010 No mobile phone-specific intervention delivery
Derose 2013 No mobile phone-specific intervention delivery
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Finkelstein 2009 No mobile phone-specific intervention delivery
Fischer 2014 No mobile phone-specific intervention delivery
Gerin 2007 No mobile phone-specific intervention delivery
Golshahi 2015 Follow-up < 12 months
Johnson 2000 No mobile phone-specific intervention delivery
Kooy 2013 No mobile phone-specific intervention delivery
Margolis 2012 No mobile phone-specific intervention delivery
McGillicuddy 2015 Kidney transplant recipient population
McManus 2010 No mobile phone-specific intervention delivery
Neafsey 2011 No mobile phone-specific intervention delivery
O’Connor 2014 No mobile phone-specific intervention delivery
Olorun 2014 Not a randomised controlled trial
Parati 2013 No mobile phone-specific intervention delivery
Richard 2016 No mobile phone-specific intervention delivery
Salisbury 2016 No mobile phone-specific intervention delivery
Vollmer 2014 No mobile phone-specific intervention delivery
Wakefield 2011 No mobile phone-specific intervention delivery
Wald 2014 Follow-up < 12 months
Warren 2012 No mobile phone-specific intervention delivery
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Choudhry 2016
Trial name or title Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment
adherence (STIC2IT): a cluster randomized pragmatic trial
Methods Design: 2-arm, cluster RCT
Setting: Harvard Vanguard Medical Associates (medical practice), MA, USA
Participants Expected: 4076
Inclusion criteria: aged 18-85 years; filled and poorly adherent (defined as a PDC < 80%) to medication for
hyperlipidaemia, hypertension or diabetes; suboptimal mean adherence to all of the qualifying medications
that a participant has filled (defined as combined (mean of means) PDC < 80%); for people with hypertension
or diabetes, poor or worsening disease control (according to relevant clinical targets)
Exclusion criteria: < 6 months of continuous enrolment in the health plan; no available contact information
Interventions Intervention: brief telephonic consultation with a clinical pharmacist using behavioural interviewing tech-
niques tailored to participant’s level of health activation and progress reports of medication taking and disease
control. Based on the barriers identified during the initial telephone consultation, participants will be offered
more intensive support including reminder and motivational text messages, video visits and pill boxes
Control group: usual care
Outcomes Primary outcome: medication adherence at 12 months (mean PDC for medications to treat eligible condi-
tions)
Secondary outcomes: disease control at 12months (proportion of participants achieving good disease control
for all eligible conditions); disease control at 12 months (proportion of participants achieving good disease
control for ≥ 1 eligible condition); healthcare utilisation at 12 months (rates of resource utilisation)
Starting date August 2015
Contact information Niteesh K Choudhry, MD, PhD; Niteesh K Choudhry, MD, PhD, Associate Professor, Harvard Medical
School, Brigham and Women’s Hospital
Notes ClinicalTrials.gov, NCT02512276
Franssen 2017
Trial name or title Telemonitoring and/or self-monitoring of blood pressure in hypertension (TASMINH4): protocol for a
randomised controlled trial
Methods Design: 3-arm, parallel RCT
Setting: UK. 144 practices recruited from the following NIHR Clinical Research Networks: Thames Valley,
West Midlands, East of England, West of England, Kent Surrey and Sussex, North West Coast, North West
London
Participants Expected: 1010
Inclusion criteria:willing and able to give informed consent for participation in the trial; men or women, aged
≥ 35 years; on practice hypertension register, not already taking > 3 antihypertensive agents and above clinic
target BP (i.e. = 140/90mmHg) at baseline (mean of 2nd/3rd readings); stable dose of current antihypertensive
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medication for ≥ 4 weeks prior to trial entry; in the Investigator’s opinion, is able and willing to comply
with all trial requirements or has a carer able to help sufficiently (e.g. in the case of physical issues with self-
monitoring); willing to allow his or her GP to be notified of participation in the trial
Exclusion criteria: BP below target at baseline (i.e. < 140/90 mmHg on clinic measurement at baseline visit);
already taking > 3 antihypertensive agents; orthostatic hypotension: > 20mmHg SBP drop after standing for 1
minute; diagnosed atrial fibrillation; unwilling to self-monitor; BPmanaged outside of primary care (including
secondary hypertension); unable to provide consent; dementia or score > 10 on the short orientation memory
concentration test (and with no carer support); women pregnant, lactating or planning pregnancy during the
course of the trial; partner or spouse of an individual already randomised in the trial; CKDGrade 4 or worse,
any grade of CKD with proteinuria; any other significant disease or disorder which, in the opinion of the
Investigator, may either put the participants at risk because of participation in the trial, or may influence the
result of the trial, or the participants ability to participate in the trial (e.g. terminal illness, house bound and
unable to attend baseline and follow-up clinics); participants who have participated in another research trial
involving an antihypertensive medication in the past 4 weeks
Interventions Intervention: Group 1: self-monitoring alone: participants will monitor their BP twice each morning and
evening (i.e. 4 times in all) for the 1st week of eachmonth. A paper record sheet will be used for communication
between paticipant and healthcare professionals in the self-monitoring alone group. GPs and nurses will be
advised to calculate the mean self-monitored BP and to use this to titrate antihypertensive medication
Group 2: telemonitoring: the frequency of self-monitoring will be identical to the self-monitoring alone group
but BP readings will be transmitted to a secure centralised database from which the GP/nurse can review the
records. Readings will be transmitted by free SMS text message. A mean BP will be automatically calculated.
High or low readings will trigger alerts to paticipant to contact their surgery for a BP check. GPs and nurses
will be advised to use the mean self-monitored BP to titrate antihypertensive medication
Control: usual care: usual care guided by clinic BP measured by the GP/practice nurse without further
instruction
Outcomes Primary outcome: SBP (mean of 2nd and 3rd BP readings) at 12 months
Secondary outcomes: SBP and DBP at 6 and 12 months; costs, health sector resource use, and acceptability
at 12 months; MARS adherence questionnaires and prescribing data at 12 months; questionnaire data on
lifestyle factors at 12 months; comparison between trial outcome data and that from clinical databases at 12
months
Starting date 1 September 2014
Contact information Richard McManus: richard.mcmanus@phc.ox.ac.uk
Nuffield Department of Primary Care, Oxford University, Oxford, UK
Notes Trial identifier: ISRCTN 83571366
Gulayin 2017
Trial name or title Educational intervention to improve effectiveness in treatment and control of patients with high cardiovascular
risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial
Methods Design: 2-arm, cluster RCT
Setting: 10 public PCCs (low-resource settings) in Argentina
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Participants Expected: 357
Inclusion criteria (for PCCs): clinic is affiliated with the Remediar programme; clinic located in a poor
urban area according to 2010 census data; clinic has ≥ 800 outpatient adult visits each month (to ensure
recruitment of enough participants); physician visits and statins are available free-of-charge to participants at
the point of care; minimum distance between PCCs is 10 km (different catchment area) and they do not share
health professionals (to minimise intervention bias); good performance of the PCCs (and their pharmacy)
according to the reports of Remediar programme
Inclusion criteria (for participants): aged ≥ 40 years and < 75 years who have received primary care at
the participating PCCs with ≥ 1 of the following criteria: arteriosclerotic CVD (defined as acute coronary
syndrome; history of myocardial infarction, stable or unstable angina, coronary revascularisation, stroke or
transient ischaemic attack presumed to be of atherosclerotic origin or revascularisation); or high CVD risk
according to theWHO charts adapted by the National MoH (estimated 10-year CVD risk≥ 20%); or LDL-
C level ≥190 mg/dL; or type 2 diabetes
Exclusion criteria: statin treatment; pregnant women; bed-bound people; unable to give informed consent;
history of end-stage chronic kidney disease treated with dialysis, HIV/AIDS, alcohol or drug abuse, or active
tuberculosis
Interventions Intervention: multi-faceted educational intervention targeting physicians and pharmacist assistants to im-
prove detection, treatment and control of hypercholesterolaemia among uninsured participants with moder-
ate-high cardiovascular risk in Argentina. Physicians belonging to the PCC randomised to the intervention
group receive a 3-component intervention: education workshop, educational outreach visits and a mHealth
application uploaded to their smartphones. In addition, 2 intervention support tools are used at the inter-
vention clinics: 1. a web-based platform that is tailored to send SMS messages for lifestyle modification, and
prompts and reminders for clinic appointments are used to improve medication adherence for participants;
2. on-site training to pharmacist assistants at the first educational outreach visit is given by physician trainers
focused on counselling to improve medication adherence among participants initiating statin therapy and at
each participant visit to the clinic to refill drug prescriptions
Control: usual care
Outcomes Primary outcome: cholesterol level (net change in LDL-C levels from baseline to month 12 between inter-
vention and usual care groups among all study participants)
Secondary outcomes: global cardiovascular risk at 1 year (net change in 10-year-CVD Framingham risk
score before and after the implementation of the programme); clinical practice guidelines compliance at 1
year (proportion of participants with high CVD risk who are on statins, and are receiving an appropriate dose
according to the clinical practice guideline); cholesterol reduction at 1 year (proportion of participants with
moderate-high CVD risk who have reduced their LDL-C by 30%, and by 50%); treatment compliance at 1
year (level of treatment adherence evaluated through questionnaire; costs of the intervention (cost-effectiveness
of the intervention programme)
Starting date April 2015
Contact information Adolfo Rubinstein, MD, MSc, PhD
Institute for Clinical Effectiveness and Health Policy; arubinstein@iecs.org.ar
Notes ClinicalTrials.gov, NCT02380911
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Trial name or title mWellcare trial: a multi-centre, cluster randomised, 12-month, controlled trial to compare the effectiveness
of mWellcare, an mHealth system for an integrated management of patients with hypertension and diabetes,
versus enhanced usual care in India
Methods Design: 2-arm, cluster RCT
Setting: India (1 southern state and 1 northern state), 40 community health centres
Participants Recruited: 3702
Inclusion criteria: participants aged≥ 30 years intending to reside in the catchment area of community health
centres for at least next 12 months. Participants were included if they were diagnosed case of hypertension
with BP measuring ≥140/90 mmHg or type 2 diabetes mellitus with fasting blood sugar ≥ 140 mg/dL or
postprandial blood sugar ≥ 200mg/dL and if they provided informed consent
Exclusion criteria: pregnant women, type 1 diabetes, requiring immediate referral to tertiary care due to
accelerated hypertension or diabetic complications, learning difficulties or vision or hearing impairments (or a
combination of these), malignancy or life-threatening disease with death probable in 4 years and not residing
in the catchment area of the community health centre
Interventions Intervention: nurses and physicians will provide treatment and follow-up using mWellcare.mWellcare system
is an Android-based mobile application designed to generate algorithm-based clinical management prompts
for treating hypertension and diabetes and also capable of storing health records. The system also sends SMS
reminders for adherence to medication and follow-up visits to participants
Control: enhanced care arm.Nurse andphysicians are provided ’refresher’ training on the clinicalmanagement
guidelines for hypertension and diabetes. Charts on management of these conditions are provided to the
facilities for prominent display at the outpatient department. Physicians in the enhanced care arm provide
the management plan based on their assessment of clinical parameters of the participants. Nurse provides
lifestyle advice brochure (in local language) and explains the same to each participant
Outcomes Primary outcomes: difference in mean change (from baseline to 1year) in SBP; difference in mean change
(from baseline to 1year) HbA1c
Secondary outcomes: difference in mean change (from baseline to 1year) of fasting plasma glucose, TC and
predicted 10-year risk of CVD using recalibrated Framingham risk score; differences in risk factors such as
depression/anxiety, smoking behaviour, BMI and alcohol uses; comparison of costs associated with delivering
the mWellcare intervention arm with respect to enhanced care
Starting date April 2016
Contact information Dr Dorairaj Prabhakaran; dprabhakaran@ccdcindia.org
Notes Clinicaltrial.gov, NCT02480062
Redfern 2014
Trial name or title A randomised controlled trial of a consumer-focused e-health strategy for cardiovascular risk management in
primary care: the Consumer Navigation of Electronic Cardiovascular Tools (CONNECT)
Methods Design: 2-arm, parallel RCT
Setting: 65 Australian General Practices and Aboriginal Community Controlled Health Services
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Participants Expected: 2000
Inclusion criteria: consenting adults (> 18 years) with access to the Internet at least once a month via mobile
phone, tablet or computer who are at moderate-to-high risk of a CVD event will be included
Moderate-to-high CVD risk is defined as any of the following: 1. 5-year CVD risk≥ 10% using the Framing-
ham risk equation; 2. a clinically high-risk condition (Aboriginal/Torres Strait Islander and aged > 75 years,
diabetes and age > 60 years, diabetes and albuminuria, epidermal growth factor receptor 7.5 mmol); 3. an
established CVD diagnosis (ischaemic heart disease, stroke/transient ischaemic attack and peripheral vascular
disease)
Exclusion criteria: severe intellectual disability or if they have insufficient English knowledge to provide
written informed consent
Interventions Intervention: CONNECT programme, a consumer-focused e-health strategy aimed at assisting with the
management and prevention of CVD in addition to usual care. Programme components focus on cardiovas-
cular risk assessment, medication adherence, lifestyle change and seamless patient-provider communication
Control group: usual healthcare.No access to the portal; however, at the end of study, all participants (control
and intervention) will be offered portal access for a maximum of 12 months
Outcomes Primary outcome: proportion of participants meeting the Australian guideline BP and lipid targets; BP 140/
90 mmHg for all except those with CVD, diabetes or albuminuria for whom the target BP is 130/80 mmHg
Secondary outcomes: proportion meeting guideline-recommended BP and LDL-C targets separately; dif-
ference in mean SBP and DBP at the end of study; difference in mean cholesterol levels at end of study (TC,
LDL-C and HDL-C); difference in mean BMI and waist circumference at the end of study; difference in
health literacy scores (HLQ51 and the eHEALS52) at end of study; cardiovascular and renal events, new
onset diabetes - self report and confirmed with medical records; physical activity - WHO Global Physical
Activity Questionnaire; point abstinence in smoking (≤ 5 cigarettes in the previous 7 days or recent smoking
according to assessment using carbon monoxide meter); fruit and vegetable intake, fish, salt and saturated fat
intake - self-report portions consumed in 7 days prior and compared with published guidelines recommenda-
tions; cardioprotective medication adherence - self-report and verified by medical record and pharmaceutical
benefits scheme data; all-cause mortality - medical record; hospital readmissions - self-report and verified by
medical record; health-related quality of life - EQ5D (version 5L with Australian standardised weights)
Starting date 17 October 2014
Contact information Dr Julie Redfern; jredfern@georgeinstitute.org.au
Notes Clinical Trials registration number ACTRN12613000715774.
Xu 2017
Trial name or title A coordinated PCP-Cardiologist Telemedicine Model (PCTM) in China’s community hypertension care:
study protocol for a randomized controlled trial
Methods Design: 3-arm, parallel RCT
Setting: 4 CHCsin XuHui District in Shanghai, China
Participants Expected: 330
Inclusion criteria: aged ≥ 21 years; clinical diagnosis of hypertension with uncontrolled BP in the previous
3 months, currently taking or about to take antihypertensive medications; received high school or above level
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of education; active user of smartphone (Android or Apple) and mobile Apps; mean of 3 BP measurements
during the screening visit at the CHC ≥ 140/90 mmHg, or ≥ 130/80 mmHg if the person has diabetes or
renal diseases; being able to give informed consent
Exclusion criteria: acute coronary syndrome; heart failure; cardiac arrhythmia; stroke within the past 3
months; renal failure; cancer; dementia, severe or acute psychiatric illness; pregnancy or intention to be
pregnant in the next 18 months; hospitalisation within 3 months; participation in another clinical trial;
arm circumference > 32 cm that may affect the accuracy of BP measurement due to cuff size limit of the
telemonitors and unwillingness to comply with the 12-month intervention duration
Interventions Intervention:Group 1: ’Self-management’ (BP telemonitor andApp-based self-management supports; patient
proficiency training)
Group 2: ’PCTM intervention’ (BP telemonitor andApp-based self-management supports; patient proficiency
training; PCP and cardiologist training of using Web-based analytics; proactive and interactive care by PCPs
and cardiologists)
Control group:management by PCPs at the registered CHCs as usual
Outcomes Primary outcome: changes in mean SBP from baseline to 12 months measured using the BP telemonitor
(Bliss BL928). The 12-month BP readings will be determined by taking the mean of 3 BP measurements at
the follow-up visit to the CHC
Secondary outcomes: changes in mean DBP from baseline to 12 months; hypertension control rate from
baseline to 6 and 12 months; hypertension control rate defined as BP < 140/90 mmHg or < 130/80 mmHg
(people with diabetes or renal diseases) following the national guidelines; changes in measures related to
hypertension complications (HbA1c, BMI and lipid levels) from baseline to 6 and 12 months; antihyper-
tensive medication adherence at baseline and 12 months assessed by self-report, 8-item Morisky Medication
Adherence Scale modified to focus on BP drugs
Starting date September 2016
Contact information Contact: Lei Xu, Master; +86-21-32260806; waqyl@126.com
Contact: Kai Liu, Doctor; +86-18918656956; liuk@carelinker.com
Notes ClinicalTrials.gov, NCT02919033
BMI: body mass index; BP: blood pressure; CHC: community healthcare centre; CKD: Chronic Kidney Disease; CVD: cardiovascular
disease; DBP: diastolic blood pressure; GP: general practitioner; HbA1c: glycated haemoglobin; HDL-C: high-density lipoprotein
cholesterol; LDL-C: low-density lipoprotein cholesterol; MARS: Medication Adherence Report Scale; mHealth: mobile health;
MoH: Minister of Health; NIHR: National Institute for Health Research; PCC: primary care centre; PCP: primary care physician;
PDC: proportion of days covered; RCT: randomised controlled trial; SBP: systolic blood pressure; SMS: short messaging service;
TC: total cholesterol; WHO: World Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. Mobile phone intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in low-density
lipoprotein cholesterol (mg/dL)
2 Mean Difference (Fixed, 95% CI) Totals not selected
2 Change in total cholesterol
(mg/dL)
2 Mean Difference (Fixed, 95% CI) Totals not selected
3 Change in high-density
lipoprotein cholesterol (mg/dL)
2 Mean Difference (Fixed, 95% CI) Totals not selected
4 Change in systolic blood pressure
(mmHg)
4 Mean Difference (Fixed, 95% CI) Totals not selected
5 Change in diastolic blood
pressure (mmHg)
3 Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Mobile phone intervention versus control, Outcome 1 Change in low-density
lipoprotein cholesterol (mg/dL).
Review: Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
Comparison: 1 Mobile phone intervention versus control
Outcome: 1 Change in low-density lipoprotein cholesterol (mg/dL)
Study or subgroup Intervention Control Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Liu 2015 238 351 0.77 (2.7603) 0.77 [ -4.64, 6.18 ]
Parraga-Martinez 2017 155 149 -9.2 (4.3368) -9.20 [ -17.70, -0.70 ]
-20 -10 0 10 20
Favours intervention Favours control
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Analysis 1.2. Comparison 1 Mobile phone intervention versus control, Outcome 2 Change in total
cholesterol (mg/dL).
Review: Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
Comparison: 1 Mobile phone intervention versus control
Outcome: 2 Change in total cholesterol (mg/dL)
Study or subgroup Intervention Control Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Liu 2015 238 351 -10.05 (3.5511) -10.05 [ -17.01, -3.09 ]
Parraga-Martinez 2017 155 149 -9.7 (4.796) -9.70 [ -19.10, -0.30 ]
-20 -10 0 10 20
Favours intervention Favours control
Analysis 1.3. Comparison 1 Mobile phone intervention versus control, Outcome 3 Change in high-density
lipoprotein cholesterol (mg/dL).
Review: Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
Comparison: 1 Mobile phone intervention versus control
Outcome: 3 Change in high-density lipoprotein cholesterol (mg/dL)
Study or subgroup Intervention Control Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Liu 2015 238 351 1.16 (1.3827) 1.16 [ -1.55, 3.87 ]
Parraga-Martinez 2017 155 149 0.1 (1.3776) 0.10 [ -2.60, 2.80 ]
-20 -10 0 10 20
Favours control Favours intervention
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Analysis 1.4. Comparison 1 Mobile phone intervention versus control, Outcome 4 Change in systolic blood
pressure (mmHg).
Review: Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
Comparison: 1 Mobile phone intervention versus control
Outcome: 4 Change in systolic blood pressure (mmHg)
Study or subgroup Intervention Control Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Bobrow 2016 (1) 457 458 -2.2 (1.1225) -2.20 [ -4.40, 0.00 ]
Bobrow 2016 (2) 457 458 -1.6 (1.0714) -1.60 [ -3.70, 0.50 ]
Liu 2015 238 351 -12.45 (1.3112) -12.45 [ -15.02, -9.88 ]
Logan 2012 (3) 54 51 -7.1 (2.3) -7.10 [ -11.61, -2.59 ]
Parraga-Martinez 2017 155 149 0.83 (1.7857) 0.83 [ -2.67, 4.33 ]
-20 -10 0 10 20
Favours intervention Favours control
(1) Information only messaging versus control
(2) Interactive messaging versus control
(3) Daytime systolic blood pressure measurement
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Analysis 1.5. Comparison 1 Mobile phone intervention versus control, Outcome 5 Change in diastolic blood
pressure (mmHg).
Review: Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
Comparison: 1 Mobile phone intervention versus control
Outcome: 5 Change in diastolic blood pressure (mmHg)
Study or subgroup Intervention Control Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Liu 2015 238 351 -12.23 (0.9184) -12.23 [ -14.03, -10.43 ]
Logan 2012 (1) 54 51 -3.9 (1.3) -3.90 [ -6.45, -1.35 ]
Parraga-Martinez 2017 155 149 1.64 (1.1174) 1.64 [ -0.55, 3.83 ]
-10 -5 0 5 10
Favours intervention Favours control
(1) Daytime diastolic blood pressure measurement
A D D I T I O N A L T A B L E S
Table 1. Indirect measures of adherence
Trial Outcome
measure
Comparison Intervention Number (in-
tervention)
Control Number
(Control)
Narrative re-
sults
Bobrow 2016
(1-year
follow-up)
Proportion of
days covered
by dispensed
medicine
Information-
only SMS vs
control
83.3% (95%
CI 69.3 to 91.
7)
457 79.2% (95%
CI 64.6 to 91.
4)
458 Median differ-
ence 5.
2, quartiles 1-
3: 1.5 to 8.9; P
= 0.006
Inter-
active SMS vs
control
83.3% (95%
CI 66.7 to 91.
7)
457 79.2% (95%
CI 64.6 to 91.
4)
458 Median differ-
ence 3.
8; quartiles 1-
3: 0.03 to 7.6;
P = 0.048
Pro-
portion of par-
ticipants with
proportion of
days covered
≥ 80%
Information-
only SMS vs
control
63% 457 49.4% 458 Adjusted odds
ratio 1.
86, 95% CI 1.
39 to 2.49; P <
0.001
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Table 1. Indirect measures of adherence (Continued)
Inter-
active SMS vs
control
60% 457 49.4% 458 Adjusted odds
ratio 1.
60, 95% CI 1.
20 to 2.16; P =
0.002
Self-
reported med-
ication ad-
herence (score
range 5-10)
Information-
only SMS vs
control
10 (quartiles
1-3: 9 to 10)
457 10 (quartiles
1-3: 9 to 10)
458 Median differ-
ence 0.
04, 95% CI -
0.1 to 0.2; P =
0.70
Inter-
active SMS vs
control
10 (quartiles
1-3: 9 to 10)
457 10 (quartiles
1-3: 9 to 10)
458 Median differ-
ence 0.
02, 95% CI -
0.2 to 0.2; P =
0.80
Parraga-
Martinez
2017
(2-year
follow-up)
Pro-
portion adher-
ent according
to self-
reported med-
ication ad-
herence (mea-
sured
using ’adapted
Morisky-
Green test’)
- 77.2% Disaggregated
not reported
64.1% Disaggregated
not reported
P = 0.029
220 in total,
not reported
by group
CI: confidence interval; SMS: short messaging service.
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (Ovid)
1 exp Cell Phones/
2 ((cell* or mobile) adj (phone* or telephon*)).tw.
3 (cellphone* or mobiles or smartphone*).tw.
4 ((mobile or handheld or hand-held or cell* or phone*) adj2 (device* or technolog* or app* or health*)).tw.
5 Text Messaging/
6 sms.tw.
7 ((text or short or multimedia or multi-media or mms) adj1 messag*).tw.
8 (texting* or texted or texter*).tw.
9 Telemedicine/
10 (mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*).tw.
11 Reminder Systems/
12 (reminder* adj (text* or system* or messag*)).tw.
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14 exp Cardiovascular Diseases/
15 cardio*.tw.
16 cardia*.tw.
17 heart*.tw.
18 coronary*.tw.
19 angina*.tw.
20 ventric*.tw.
21 myocard*.tw.
22 pericard*.tw.
23 isch?em*.tw.
24 emboli*.tw.
25 arrhythmi*.tw.
26 thrombo*.tw.
27 atrial fibrillat*.tw.
28 tachycardi*.tw.
29 endocardi*.tw.
30 (sick adj sinus).tw.
31 hypertensi*.tw.
32 exp Hyperlipidemias/
33 hyperlipid*.tw.
34 hyperlip?emia*.tw.
35 hypercholesterol*.tw.
36 hypercholester?emia*.tw.
37 hyperlipoprotein?emia*.tw.
38 hypertriglycerid?emia*.tw.
39 arteriosclerosis.tw.
40 atherosclerosis.tw.
41 exp Cholesterol/
42 cholesterol.tw.
43 Blood Pressure/
44 ((high* or raise* or elevat* or heighten* or increas*) adj3 (blood adj2 pressure)).tw.
45 ((high* or raise* or elevat* or heighten* or increas*) adj3 (BP or DBP or SBP)).tw.
46 ((diastolic or systolic or pulse) adj pressure).tw.
47 exp Stroke/
48 (stroke or strokes).tw.
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49 cerebrovasc*.tw.
50 cerebral vascular.tw.
51 apoplexy.tw.
52 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
53 peripheral arter* disease*.tw.
54 aortic*.tw.
55 (arterial adj occlus*).tw.
56 infarct*.tw.
57 multiple risk factor.tw.
58 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57
59 randomized controlled trial.pt.
60 controlled clinical trial.pt.
61 randomized.ab.
62 placebo.ab.
63 clinical trials as topic.sh.
64 randomly.ab.
65 trial.ti.
66 59 or 60 or 61 or 62 or 63 or 64 or 65
67 exp animals/ not humans.sh.
68 66 not 67
69 13 and 58 and 68
CENTRAL
#1 MeSH descriptor: [Cell Phones] explode all trees
#2 ((cell* or mobile) near (phone* or telephon*))
#3 (cellphone* or mobiles or smartphone*)
#4 ((mobile or handheld or hand-held or cell* or phone*) near/2 (device* or technolog* or app* or health*))
#5 MeSH descriptor: [Text Messaging] this term only
#6 sms
#7 ((text or short or multimedia or multi-media or mms) near/1 messag*)
#8 (texting* or texted or texter*)
#9 MeSH descriptor: [Telemedicine] this term only
#10 (mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*)
#11 MeSH descriptor: [Reminder Systems] this term only
#12 (reminder* near (text* or system* or messag*))
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#15 cardio*
#16 cardia*
#17 heart*
#18 coronary*
#19 angina*
#20 ventric*
#21 myocard*
#22 pericard*
#23 isch*em*
#24 emboli*
#25 arrhythmi*
#26 thrombo*
#27 atrial fibrillat*
#28 tachycardi*
#29 endocardi*
#30 (sick near sinus)
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#31 hypertensi*
#32 MeSH descriptor: [Hyperlipidemias] explode all trees
#33 hyperlipid*
#34 hyperlip*emia*
#35 hypercholesterol*
#36 hypercholester*emia*
#37 hyperlipoprotein*emia*
#38 hypertriglycerid*emia*
#39 arteriosclerosis
#40 atherosclerosis
#41 MeSH descriptor: [Cholesterol] explode all trees
#42 cholesterol
#43 MeSH descriptor: [Blood Pressure] this term only
#44 ((high* or raise* or elevat* or heighten* or increas*) near/3 (blood near/2 pressure))
#45 ((high* or raise* or elevat* or heighten* or increas*) near/3 (BP or DBP or SBP))
#46 ((diastolic or systolic or pulse) near pressure)
#47 MeSH descriptor: [Stroke] explode all trees
#48 (stroke or strokes)
#49 cerebrovasc*
#50 cerebral vascular
#51 apoplexy
#52 ((brain* or cerebral or lacunar) near/2 infarct*)
#53 peripheral arter* disease*
#54 aortic*
#55 (arterial near occlus*)
#56 infarct*
#57 multiple risk factor
#58 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or
#50 or #51 or #52 or #53 or #54 or #55 or #56 or #57
#59 #13 and #58
Embase
1. exp mobile phone/
2. ((cell* or mobile) adj (phone* or telephon*)).tw.
3. (cellphone* or mobiles or smartphone*).tw.
4. ((mobile or handheld or hand-held or cell* or phone*) adj2 (device* or technolog* or app* or health*)).tw.
5. text messaging/
6. sms.tw.
7. ((text or short or multimedia or multi-media or mms) adj1 messag*).tw.
8. (texting* or texted or texter*).tw.
9. telemedicine/
10. (mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*).tw.
11. reminder system/
12. (reminder* adj (text* or system* or messag*)).tw.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp cardiovascular disease/
15. cardio*.tw.
16. cardia*.tw.
17. heart*.tw.
18. coronary*.tw.
19. angina*.tw.
20. ventric*.tw.
21. myocard*.tw.
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22. pericard*.tw.
23. isch?em*.tw.
24. emboli*.tw.
25. arrhythmi*.tw.
26. thrombo*.tw.
27. atrial fibrillat*.tw.
28. tachycardi*.tw.
29. endocardi*.tw.
30. (sick adj sinus).tw.
31. hypertensi*.tw.
32. exp Hyperlipidemias/
33. hyperlipid*.tw.
34. hyperlip?emia*.tw.
35. hypercholesterol*.tw.
36. hypercholester?emia*.tw.
37. hyperlipoprotein?emia*.tw.
38. hypertriglycerid?emia*.tw.
39. arteriosclerosis.tw.
40. atherosclerosis.tw.
41. exp cholesterol/
42. cholesterol.tw.
43. blood pressure/
44. ((high* or raise* or elevat* or heighten* or increas*) adj3 (blood adj2 pressure)).tw.
45. ((high* or raise* or elevat* or heighten* or increas*) adj3 (BP or DBP or SBP)).tw.
46. ((diastolic or systolic or pulse) adj pressure).tw.
47. exp cerebrovascular accident/
48. (stroke or strokes).tw.
49. cerebrovasc*.tw.
50. cerebral vascular.tw.
51. apoplexy.tw.
52. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
53. peripheral arter* disease*.tw.
54. aortic*.tw.
55. (arterial adj occlus*).tw.
56. infarct*.tw.
57. multiple risk factor.tw.
58. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57
59. random$.tw.
60. factorial$.tw.
61. crossover$.tw.
62. cross over$.tw.
63. cross-over$.tw.
64. placebo$.tw.
65. (doubl$ adj blind$).tw.
66. (singl$ adj blind$).tw.
67. assign$.tw.
68. allocat$.tw.
69. volunteer$.tw.
70. crossover procedure/
71. double blind procedure/
72. randomized controlled trial/
73. single blind procedure/
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74. 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73
75. (animal/ or nonhuman/) not human/
76. 74 not 75
77. 13 and 58 and 76
CINAHL Plus
S71 S13 AND S58 AND S70
S70 S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69
S69 TX allocat* random*
S68 (MH “Quantitative Studies”)
S67 (MH “Placebos”)
S66 TX placebo*
S65 TX random* allocat*
S64 (MH “Random Assignment”)
S63 TX randomi* control* trial*
S62 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S61 TX clinic* n1 trial*
S60 PT Clinical trial
S58 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43
OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57
S57 TI multiple risk factor or AB multiple risk factor
S56 TI infarct* or AB infarct*
S55 TI (arterial N0 occlus*) or AB (arterial N0 occlus*)
S54 TI aortic* or AB aortic*
S53 TI peripheral arter* disease* or AB peripheral arter* disease*
S52 TI ((brain* or cerebral or lacunar) N2 infarct*) or AB ((brain* or cerebral or lacunar) N2 infarct*)
S51 TI apoplexy or AB apoplexy
S50 TI cerebral vascular or AB cerebral vascular
S49 TI cerebrovasc* or AB cerebrovasc*
S48 TI (stroke or strokes) or AB (stroke or strokes)
S47 (MH “Stroke+”)
S46 TI ((diastolic or systolic or pulse) N0 pressure) or AB ((diastolic or systolic or pulse) N0 pressure)
S45 TI ((high* or raise* or elevat* or heighten* or increas*) N3 (BP or DBP or SBP)) or AB ((high* or raise* or elevat* or heighten*
or increas*) N3 (BP or DBP or SBP))
S44 TI ((high* or raise* or elevat* or heighten* or increas*) N3 (blood N2 pressure)) or AB ((high* or raise* or elevat* or heighten* or
increas*) N3 (blood N2 pressure))
S43 (MH “Blood Pressure”)
S42 TI cholesterol or AB cholesterol
S41 (MH “Cholesterol+”)
S40 TI atherosclerosis or AB atherosclerosis
S39 TI arteriosclerosis or AB arteriosclerosis
S38 TI hypertriglycerid?emia* or AB hypertriglycerid?emia*
S37 TI hyperlipoprotein?emia* or AB hyperlipoprotein?emia*
S36 TI hypercholester?emia* or AB hypercholester?emia*
S35 TI hypercholesterol* or AB hypercholesterol*
S34 TI hyperlip?emia* or AB hyperlip?emia*
S33 TI hyperlipid* or AB hyperlipid*
S32 (MH “Hyperlipidemia+”)
S31 TI hypertensi* or AB hypertensi*
S30 TI (sick N0 sinus) or AB (sick N0 sinus)
S29 TI endocardi* or AB endocardi*
S28 TI tachycardi* or AB tachycardi*
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S27 TI atrial fibrillat* or AB atrial fibrillat*
S26 TI thrombo* or AB thrombo*
S25 TI arrhythmi* or AB arrhythmi*
S24 TI emboli* or AB emboli*
S23 TI isch?em* or AB isch?em*
S22 TI pericard* or AB pericard*
S21 TI myocard* or AB myocard*
S20 TI ventric* or AB ventric*
S19 TI angina* or AB angina*
S18 TI coronary* or AB coronary*
S17 TI heart* or AB heart*
S16 TI cardia* or AB cardia*
S15 TI cardio* or AB cardio*
S14 (MH “Cardiovascular Diseases+”)
S13 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 TI (reminder* N0 (text* or system* or messag*)) or AB (reminder* N0 (text* or system* or messag*))
S11 (MH “Reminder Systems”)
S10 TI (mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*) or AB (mhealth or m-health or
ehealth or e-health or telemedicine* or telehealth or telemonitor*)
S9 (MH “Telemedicine”)
S8 TI (texting* or texted or texter*) or AB (texting* or texted or texter*)
S7 TI ((text or short or multimedia or multi-media or mms) N1 messag*) or AB ((text or short or multimedia or multi-media or mms)
N1 messag*)
S6 TI sms or AB sms
S5 (MH “Text Messaging”)
S4 TI ((mobile or handheld or hand-held or cell* or phone*) N2 (device* or technolog* or app* or health*)) or AB ((mobile or handheld
or hand-held or cell* or phone*) N2 (device* or technolog* or app* or health*))
S3 TI (cellphone* or mobiles or smartphone*) or AB (cellphone* or mobiles or smartphone*)
S2 TI ((cell* or mobile) N0 (phone* or telephon*)) or AB ((cell* or mobile) N0 (phone* or telephon*))
S1 (MH “Cellular Phone+”)
Conference Proceedings Citation Index-Science (CPCI-S)
# 23 #22 AND #21 AND #8
# 22 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
# 20 TS=(arterial near occlus*)
# 19 TS=(aortic* or infarct* or multiple risk factor)
# 18 TS=peripheral arter* disease*
# 17 TS=((brain* or cerebral or lacunar) near/2 infarct*)
# 16 TS=(cerebrovasc* or cerebral vascular or apoplexy)
# 15 TS=(stroke or strokes)
# 14 TS=((diastolic or systolic or pulse) near pressure)
# 13 TS=((high* or raise* or elevat* or heighten* or increas*) near/3 (BP or DBP or SBP))
# 12 TS=((high* or raise* or elevat* or heighten* or increas*) near/3 (blood near/2 pressure))
# 11 TS=(hypertensi* or hyperlipid* or hyperlip?emia* or hypercholesterol* or hypercholester?emia* or hyperlipoprotein?emia* or
hypertriglycerid?emia* or arteriosclerosis or atherosclerosis or cholesterol)
# 10 TS=(sick near sinus)
# 9 TS=(cardio* or cardia* or heart* or coronary* or angina* or ventric* or myocard* or pericard* or isch?em* or emboli* or arrhythmi*
or thrombo* or atrial fibrillat* or tachycardi* or endocardi*)
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 7 TS=(reminder* near (text* or system* or messag*))
# 6 TS=(mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*)
# 5 TS=(sms or texting* or texted or texter*)
# 4 TS=((text or short or multimedia or multi-media or mms) near/1 messag*)
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# 3 TS=((mobile or handheld or hand-held or cell* or phone*) near/2 (device* or technolog* or app* or health*))
# 2 TS=(cellphone* or mobiles or smartphone*)
# 1 TS=((cell* or mobile) near (phone* or telephon*))
ClinicalTrials.gov
Condition or disease: CVD OR “blood pressure” OR cholesterol
Other terms: “mobile phone” “medication”
Study type: Interventional Studies (Clinical Trials)
WHO International Clinical Trials Registry Platform (ICTRP)
Condition: CVD OR “blood pressure” OR cholesterol
AND
Intervention: “mobile phone”
C O N T R I B U T I O N S O F A U T H O R S
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SB: none known.
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disease. We are likely to apply for funding for a randomised controlled trial to evaluate its effects.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In our protocol, we specified howwe would deal with trials that included amix of participants meeting the criteria of primary prevention
and secondary prevention of CVD, stating: “where we identify trials that include a subset of eligible participants, we will contact the
authors to request data for only those participants of interest. In the event that we are unable to access these data, we will apply a cut-
off whereby only trials in which at least 75% of participants meet the criteria for primary prevention will be included.”
However, we did not specify how we would deal with trials that included a mix of participants who were prescribed CVD prevention
medication and participants who were not prescribed CVD medication. Given that we stated we would include trials of interventions
that target medication adherence alongside other lifestyle modifications, three of our trials identified for inclusion in this review
included participants who had, and participants who had not, been prescribed CVD prevention medication (Liu 2015; Logan 2012;
Parraga-Martinez 2017). We contacted trial authors to request the trial data for only these participants, but we did not receive
responses. Therefore, we extracted primary outcome data of objective measures of medication adherence (e.g. blood pressure, low-
density lipoprotein cholesterol, etc.) for these mixed populations.
We stated that we would extract low-density lipoprotein cholesterol as an objective indicator of adherence to lipid-lowering medication.
In addition, we have also extracted total cholesterol and high-density lipoprotein cholesterol.
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